The Role of Substance P

In

Experimental Intracerebral Haemorrhage

Timothy J. Kleinig, M.B.B.S. (Hons.), B.A., F.R.A.C.P.

Discipline of Pathology, School of Medical Sciences,

University of Adelaide

May 2010

A thesis submitted in partial fulfilment of the requirements for the degree of Doctor of Philosophy

References

159

References: 1. Hatano S. Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ 1976;54:541-53.

2. Seshadri S, Beiser A, Kelly-Hayes M, et al. The lifetime risk of stroke: estimates from the Framingham Study. Stroke 2006;37:345-50.

3. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;367:1747-57.

4. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge, MA: Harvard University Press; 1996.

5. Mathers CD, Vos ET, Stevenson CE, Begg SJ. The Australian Burden of Disease Study: measuring the loss of health from diseases, injuries and risk factors. Med J Aust 2000;172:592-6.

6. Dewey HM, Thrift AG, Mihalopoulos C, et al. Cost of stroke in Australia from a societal perspective: results from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2001;32:2409-16.

7. Qureshi AI, Mendelow AD, Hanley DF. Intracerebral haemorrhage. Lancet 2009;373:1632-44.

8. Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF. Spontaneous intracerebral hemorrhage. N Engl J Med 2001;344:1450-60.

9. Ferro JM. Update on intracerebral haemorrhage. J Neurol 2006;253:985-99.

10. Iso H, Jacobs DR, Jr., Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989;320:904-10.

11. Flaherty ML, Woo D, Haverbusch M, et al. Racial variations in location and risk of intracerebral hemorrhage. Stroke 2005;36:934-7.

12. Qureshi AI, Suri MF, Nasar A, et al. Changes in cost and outcome among US patients with stroke hospitalized in 1990 to 1991 and those hospitalized in 2000 to 2001. Stroke 2007;38:2180-4.

13. Flaherty ML, Kissela B, Woo D, et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology 2007;68:116-21.

14. Jamrozik K, Broadhurst RJ, Lai N, Hankey GJ, Burvill PW, Anderson CS. Trends in the incidence, severity, and short-term outcome of stroke in perth, Western Australia. Stroke 1999;30:2105-11.

15. Mathers CD, Vos ET, Stevenson CE, Begg SJ. The burden of disease and injury in Australia. Bull World Health Organ 2001;79:1076-84.

16. Broderick JP, Brott T, Tomsick T, Miller R, Huster G. Intracerebral hemorrhage more than twice as common as subarachnoid hemorrhage. J Neurosurg 1993;78:188-91.

17. Dennis MS, Burn JP, Sandercock PA, Bamford JM, Wade DT, Warlow CP. Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke 1993;24:796-800.

18. Anderson CS, Chakera TM, Stewart-Wynne EG, Jamrozik KD. Spectrum of primary intracerebral haemorrhage in Perth, Western Australia, 1989-90: incidence and outcome. J Neurol Neurosurg Psychiatry 1994;57:936-40.

19. Thrift AG, Dewey HM, Macdonell RA, McNeil JJ, Donnan GA. Incidence of the major stroke subtypes: initial findings from the North East Melbourne stroke incidence study (NEMESIS). Stroke 2001;32:1732-8.

References

160

20. Sturm JW, Dewey HM, Donnan GA, Macdonell RA, McNeil JJ, Thrift AG. Handicap after stroke: how does it relate to disability, perception of recovery, and stroke subtype?: the north North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2002;33:762-8.

21. Dewey HM, Thrift AG, Mihalopoulos C, et al. Lifetime cost of stroke subtypes in Australia: findings from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2003;34:2502-7.

22. Fisher CM. Pathological observations in hypertensive cerebral hemorrhage. J Neuropathol Exp Neurol 1971;30:536-50.

23. Takebayashi S, Kaneko M. Electron microscopic studies of ruptured arteries in hypertensive intracerebral hemorrhage. Stroke 1983;14:28-36.

24. Fisher CM. Hypertensive cerebral hemorrhage. Demonstration of the source of bleeding. J Neuropathol Exp Neurol 2003;62:104-7.

25. Kittner SJ, Stern BJ, Feeser BR, et al. Pregnancy and the risk of stroke. N Engl J Med 1996;335:768-74.

26. Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke 2005;36:1588-93.

27. Smith EE, Eichler F. Cerebral amyloid angiopathy and lobar intracerebral hemorrhage. Arch Neurol 2006;63:148-51.

28. Steiner T, Rosand J, Diringer M. Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke 2006;37:256-62.

29. Ritter MA, Droste DW, Hegedus K, et al. Role of cerebral amyloid angiopathy in intracerebral hemorrhage in hypertensive patients. Neurology 2005;64:1233-7.

30. Zhu XL, Chan MS, Poon WS. Spontaneous intracranial hemorrhage: which patients need diagnostic cerebral angiography? A prospective study of 206 cases and review of the literature. Stroke 1997;28:1406-9.

31. Ariesen MJ, Claus SP, Rinkel GJ, Algra A. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke 2003;34:2060-5.

32. Perry HM, Jr., Davis BR, Price TR, et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). Jama 2000;284:465-71.

33. Woo D, Haverbusch M, Sekar P, et al. Effect of untreated hypertension on hemorrhagic stroke. Stroke 2004;35:1703-8.

34. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.

35. Kurth T, Kase CS, Berger K, Gaziano JM, Cook NR, Buring JE. Smoking and risk of hemorrhagic stroke in women. Stroke 2003;34:2792-5.

36. Kurth T, Kase CS, Berger K, Schaeffner ES, Buring JE, Gaziano JM. Smoking and the risk of hemorrhagic stroke in men. Stroke 2003;34:1151-5.

37. Thrift AG, Donnan GA, McNeil JJ. Heavy drinking, but not moderate or intermediate drinking, increases the risk of intracerebral hemorrhage. Epidemiology 1999;10:307-12.

38. Iso H, Baba S, Mannami T, et al. Alcohol consumption and risk of stroke among middle-aged men: the JPHC Study Cohort I. Stroke 2004;35:1124-9.

39. Sturgeon JD, Folsom AR, Longstreth WT, Jr., Shahar E, Rosamond WD, Cushman M. Hemostatic and inflammatory risk factors for intracerebral hemorrhage in a pooled cohort. Stroke 2008;39:2268-73.

40. Goldstein LB, Amarenco P, Szarek M, et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 2008;70:2364-70.

References

161

41. Greenberg SM, Vernooij MW, Cordonnier C, et al. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol 2009;8:165-74.

42. Bailey RD, Hart RG, Benavente O, Pearce LA. Recurrent brain hemorrhage is more frequent than ischemic stroke after intracranial hemorrhage. Neurology 2001;56:773-7.

43. Buhl R, Barth H, Mehdorn HM. Risk of recurrent intracerebral hemorrhages. Neurol Res 2003;25:853-6.

44. Hanger HC, Wilkinson TJ, Fayez-Iskander N, Sainsbury R. The risk of recurrent stroke after intracerebral haemorrhage. J Neurol Neurosurg Psychiatry 2007;78:836-40.

45. Yen CC, Lo YK, Li JY, Lin YT, Lin CH, Gau YY. Recurrent primary intracerebral hemorrhage: a hospital based study. Acta Neurol Taiwan 2007;16:74-80.

46. Woo D, Kaushal R, Chakraborty R, et al. Association of apolipoprotein E4 and haplotypes of the apolipoprotein E gene with lobar intracerebral hemorrhage. Stroke 2005;36:1874-9.

47. Navarro-Nunez L, Lozano ML, Rivera J, et al. The association of the beta1-tubulin Q43P polymorphism with intracerebral hemorrhage in men. Haematologica 2007;92:513-8.

48. Strand M, Soderstrom I, Wiklund PG, et al. Polymorphisms at the osteoprotegerin and interleukin-6 genes in relation to first-ever stroke. Cerebrovasc Dis 2007;24:418-25.

49. Strand M, Soderstrom I, Wiklund PG, et al. Estrogen Receptor Alpha Gene Polymorphisms and First-Ever Intracerebral Hemorrhage. Cerebrovasc Dis 2007;24:500-8.

50. Achrol AS, Kim H, Pawlikowska L, et al. Association of tumor necrosis factor-alpha-238G>A and Apolipoprotein E2 polymorphisms with intracranial hemorrhage after brain arteriovenous malformation treatment. Neurosurgery 2007;61:731-9; discussion 40.

51. O'Donnell HC, Rosand J, Knudsen KA, et al. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med 2000;342:240-5.

52. Palsdottir A, Abrahamson M, Thorsteinsson L, et al. Mutation in cystatin C gene causes hereditary brain haemorrhage. Lancet 1988;2:603-4.

53. Levy E, Carman MD, Fernandez-Madrid IJ, et al. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 1990;248:1124-6.

54. Vahedi K, Boukobza M, Massin P, Gould DB, Tournier-Lasserve E, Bousser MG. Clinical and brain MRI follow-up study of a family with COL4A1 mutation. Neurology 2007;69:1564-8.

55. Laberge-le Couteulx S, Jung HH, Labauge P, et al. Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas. Nat Genet 1999;23:189-93.

56. Broderick JP, Brott TG, Duldner JE, Tomsick T, Huster G. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke 1993;24:987-93.

57. Xi G, Keep RF, Hoff JT. Mechanisms of brain injury after intracerebral haemorrhage. Lancet Neurol 2006;5:53-63.

58. Ruiz-Sandoval JL, Chiquete E, Romero-Vargas S, Padilla-Martinez JJ, Gonzalez-Cornejo S. Grading scale for prediction of outcome in primary intracerebral hemorrhages. Stroke 2007;38:1641-4.

59. Hemphill JC, 3rd, Bonovich DC, Besmertis L, Manley GT, Johnston SC. The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. Stroke 2001;32:891-7.

60. Kalimo H, Kaste M, Haltia M. Vascular diseases. In: Graham DI, Lantos PL, eds. Greenfield's Neuropathology. Seventh ed. London: Arnold; 2002:281-355.

61. Whisnant JP, Sayre GP, Millikan CH. Experimental intracerebral hematoma. Arch Neurol 1963;9:586-92.

62. Rosenberg GA, Mun-Bryce S, Wesley M, Kornfeld M. Collagenase-induced intracerebral hemorrhage in rats. Stroke 1990;21:801-7.

References

162

63. Yang GY, Betz AL, Chenevert TL, Brunberg JA, Hoff JT. Experimental intracerebral hemorrhage: relationship between brain edema, blood flow, and blood-brain barrier permeability in rats. J Neurosurg 1994;81:93-102.

64. Xue M, Del Bigio MR. Intracerebral injection of autologous whole blood in rats: time course of inflammation and cell death. Neurosci Lett 2000;283:230-2.

65. Gong C, Hoff JT, Keep RF. Acute inflammatory reaction following experimental intracerebral hemorrhage in rat. Brain Res 2000;871:57-65.

66. Takasugi S, Ueda S, Matsumoto K. Chronological changes in spontaneous intracerebral hematoma--an experimental and clinical study. Stroke 1985;16:651-8.

67. Enzmann DR, Britt RH, Lyons BE, Buxton JL, Wilson DA. Natural history of experimental intracerebral hemorrhage: sonography, computed tomography and neuropathology. AJNR Am J Neuroradiol 1981;2:517-26.

68. Wisniewski H. The pathogenesis of some cases of cerebral hemorrhage (a morphologic study of the margins of hemorrhagic foci and areas of the brain distant form the hemorrhage). Acta Med Pol 1961;2:379-90.

69. Mackenzie JM, Clayton JA. Early cellular events in the penumbra of human spontaneous intracerebral hemorrhage. J Stroke Cerebrovasc Dis 1999;8:1-8.

70. Gebel JM, Brott TG, Sila CA, et al. Decreased perihematomal edema in thrombolysis-related intracerebral hemorrhage compared with spontaneous intracerebral hemorrhage. Stroke 2000;31:596-600.

71. Gebel JM, Jr., Jauch EC, Brott TG, et al. Natural history of perihematomal edema in patients with hyperacute spontaneous intracerebral hemorrhage. Stroke 2002;33:2631-5.

72. Suga S, Sato S, Yunoki K, Mihara B. Sequential change of brain edema by semiquantitative measurement on MRI in patients with hypertensive intracerebral hemorrhage. Acta Neurochir Suppl (Wien) 1994;60:564-7.

73. Wu G, Xi G, Huang F. Spontaneous intracerebral hemorrhage in humans: hematoma enlargement, clot lysis, and brain edema. Acta Neurochir Suppl 2006;96:78-80.

74. Kreel L, Kay R, Woo J, Wong HY, Nicholls MG. The radiological (CT) and clinical sequelae of primary intracerebral haemorrhage. Br J Radiol 1991;64:1096-100.

75. Franke CL, van Swieten JC, van Gijn J. Residual lesions on computed tomography after intracerebral hemorrhage. Stroke 1991;22:1530-3.

76. Skriver EB, Olsen TS. Tissue damage at computed tomography following resolution of intracerebral hematomas. Acta Radiol Diagn (Stockh) 1986;27:495-500.

77. Smith EE, Rosand J, Greenberg SM. Imaging of hemorrhagic stroke. Magn Reson Imaging Clin N Am 2006;14:127-40, v.

78. Kidwell CS, Chalela JA, Saver JL, et al. Comparison of MRI and CT for detection of acute intracerebral hemorrhage. Jama 2004;292:1823-30.

79. Astrup J, Siesjo BK, Symon L. Thresholds in cerebral ischemia - the ischemic penumbra. Stroke 1981;12:723-5.

80. Nehls DG, Mendelow AD, Graham DI, Sinar EJ, Teasdale GM. Experimental intracerebral hemorrhage: progression of hemodynamic changes after production of a spontaneous mass lesion. Neurosurgery 1988;23:439-44.

81. Ropper AH, Zervas NT. Cerebral blood flow after experimental basal ganglia hemorrhage. Ann Neurol 1982;11:266-71.

82. Tanaka A, Yoshinaga S, Nakayama Y, Kimura M, Tomonaga M. Cerebral blood flow and clinical outcome in patients with thalamic hemorrhages: a comparison with putaminal hemorrhages. J Neurol Sci 1996;144:191-7.

References

163

83. Zazulia AR, Diringer MN, Videen TO, et al. Hypoperfusion without ischemia surrounding acute intracerebral hemorrhage. J Cereb Blood Flow Metab 2001;21:804-10.

84. Qureshi AI, Wilson DA, Hanley DF, Traystman RJ. No evidence for an ischemic penumbra in massive experimental intracerebral hemorrhage. Neurology 1999;52:266-72.

85. Carhuapoma JR, Wang PY, Beauchamp NJ, Keyl PM, Hanley DF, Barker PB. Diffusion-weighted MRI and proton MR spectroscopic imaging in the study of secondary neuronal injury after intracerebral hemorrhage. Stroke 2000;31:726-32.

86. Herweh C, Juttler E, Schellinger PD, et al. Evidence against a perihemorrhagic penumbra provided by perfusion computed tomography. Stroke 2007;38:2941-7.

87. Wagner KR, Xi G, Hua Y, Kleinholz M, de Courten-Myers GM, Myers RE. Early metabolic alterations in edematous perihematomal brain regions following experimental intracerebral hemorrhage. J Neurosurg 1998;88:1058-65.

88. Miller CM, Vespa PM, McArthur DL, Hirt D, Etchepare M. Frameless stereotactic aspiration and thrombolysis of deep intracerebral hemorrhage is associated with reduced levels of extracellular cerebral glutamate and unchanged lactate pyruvate ratios. Neurocrit Care 2007;6:22-9.

89. Carmichael ST, Vespa PM, Saver JL, et al. Genomic profiles of damage and protection in human intracerebral hemorrhage. J Cereb Blood Flow Metab 2008;28:1860-75.

90. Lu A, Tang Y, Ran R, Ardizzone TL, Wagner KR, Sharp FR. Brain genomics of intracerebral hemorrhage. J Cereb Blood Flow Metab 2006;26:230-52.

91. Mayer SA, Sacco RL, Shi T, Mohr JP. Neurologic deterioration in noncomatose patients with supratentorial intracerebral hemorrhage. Neurology 1994;44:1379-84.

92. Broderick JP, Brott TG, Tomsick T, Barsan W, Spilker J. Ultra-early evaluation of intracerebral hemorrhage. J Neurosurg 1990;72:195-9.

93. Kazui S, Naritomi H, Yamamoto H, Sawada T, Yamaguchi T. Enlargement of spontaneous intracerebral hemorrhage. Incidence and time course. Stroke 1996;27:1783-7.

94. Fujii Y, Tanaka R, Takeuchi S, Koike T, Minakawa T, Sasaki O. Hematoma enlargement in spontaneous intracerebral hemorrhage. J Neurosurg 1994;80:51-7.

95. Fujii Y, Takeuchi S, Sasaki O, Minakawa T, Tanaka R. Multivariate analysis of predictors of hematoma enlargement in spontaneous intracerebral hemorrhage. Stroke 1998;29:1160-6.

96. Brott T, Broderick J, Kothari R, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 1997;28:1-5.

97. Silva Y, Leira R, Tejada J, Lainez JM, Castillo J, Davalos A. Molecular signatures of vascular injury are associated with early growth of intracerebral hemorrhage. Stroke 2005;36:86-91.

98. Wang J, Dore S. Inflammation after intracerebral hemorrhage. J Cereb Blood Flow Metab 2007;27:894-908.

99. Davis SM, Broderick J, Hennerici M, et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 2006;66:1175-81.

100. Fogelholm R, Nuutila M, Vuorela AL. Primary intracerebral haemorrhage in the Jyvaskyla region, central Finland, 1985-89: incidence, case fatality rate, and functional outcome. J Neurol Neurosurg Psychiatry 1992;55:546-52.

101. Goldstein JN, Fazen LE, Snider R, et al. Contrast extravasation on CT angiography predicts hematoma expansion in intracerebral hemorrhage. Neurology 2007;68:889-94.

102. Wada R, Aviv RI, Fox AJ, et al. CT angiography "spot sign" predicts hematoma expansion in acute intracerebral hemorrhage. Stroke 2007;38:1257-62.

References

164

103. Becker KJ, Baxter AB, Bybee HM, Tirschwell DL, Abouelsaad T, Cohen WA. Extravasation of radiographic contrast is an independent predictor of death in primary intracerebral hemorrhage. Stroke 1999;30:2025-32.

104. Murai Y, Ikeda Y, Teramoto A, Tsuji Y. Magnetic resonance imaging-documented extravasation as an indicator of acute hypertensive intracerebral hemorrhage. J Neurosurg 1998;88:650-5.

105. Flibotte JJ, Hagan N, O'Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 2004;63:1059-64.

106. Toyoda K, Okada Y, Minematsu K, et al. Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage. Neurology 2005;65:1000-4.

107. Broderick JP, Diringer MN, Hill MD, et al. Determinants of intracerebral hemorrhage growth: an exploratory analysis. Stroke 2007;38:1072-5.

108. Tuhrim S, Horowitz DR, Sacher M, Godbold JH. Volume of ventricular blood is an important determinant of outcome in supratentorial intracerebral hemorrhage. Crit Care Med 1999;27:617-21.

109. Young WB, Lee KP, Pessin MS, Kwan ES, Rand WM, Caplan LR. Prognostic significance of ventricular blood in supratentorial hemorrhage: a volumetric study. Neurology 1990;40:616-9.

110. Leira R, Davalos A, Silva Y, et al. Early neurologic deterioration in intracerebral hemorrhage: predictors and associated factors. Neurology 2004;63:461-7.

111. Bhattathiri PS, Gregson B, Prasad KS, Mendelow AD. Intraventricular hemorrhage and hydrocephalus after spontaneous intracerebral hemorrhage: results from the STICH trial. Acta Neurochir Suppl 2006;96:65-8.

112. Diringer MN, Edwards DF, Zazulia AR. Hydrocephalus: a previously unrecognized predictor of poor outcome from supratentorial intracerebral hemorrhage. Stroke 1998;29:1352-7.

113. Phan TG, Koh M, Vierkant RA, Wijdicks EF. Hydrocephalus is a determinant of early mortality in putaminal hemorrhage. Stroke 2000;31:2157-62.

114. Hanley DF. Intraventricular hemorrhage: severity factor and treatment target in spontaneous intracerebral hemorrhage. Stroke 2009;40:1533-8.

115. Nyquist P, Hanley DF. The use of intraventricular thrombolytics in intraventricular hemorrhage. J Neurol Sci 2007;261:84-8.

116. Pang D, Sclabassi RJ, Horton JA. Lysis of intraventricular blood clot with urokinase in a canine model: Part 3. Effects of intraventricular urokinase on clot lysis and posthemorrhagic hydrocephalus. Neurosurgery 1986;19:553-72.

117. Mayfrank L, Kissler J, Raoofi R, et al. Ventricular dilatation in experimental intraventricular hemorrhage in pigs. Characterization of cerebrospinal fluid dynamics and the effects of fibrinolytic treatment. Stroke 1997;28:141-8.

118. Wang YC, Lin CW, Shen CC, Lai SC, Kuo JS. Tissue plasminogen activator for the treatment of intraventricular hematoma: the dose-effect relationship. J Neurol Sci 2002;202:35-41.

119. Mayfrank L, Kim Y, Kissler J, et al. Morphological changes following experimental intraventricular haemorrhage and intraventricular fibrinolytic treatment with recombinant tissue plasminogen activator. Acta Neuropathol 2000;100:561-7.

120. Morgan T, Awad I, Keyl P, Lane K, Hanley D. Preliminary report of the clot lysis evaluating accelerated resolution of intraventricular hemorrhage (CLEAR-IVH) clinical trial. Acta Neurochir Suppl 2008;105:217-20.

121. Ropper AH, King RB. Intracranial pressure monitoring in comatose patients with cerebral hemorrhage. Arch Neurol 1984;41:725-8.

122. Ropper AH. Lateral displacement of the brain and level of consciousness in patients with an acute hemispheral mass. N Engl J Med 1986;314:953-8.

References

165

123. Zazulia AR, Diringer MN, Derdeyn CP, Powers WJ. Progression of mass effect after intracerebral hemorrhage. Stroke 1999;30:1167-73.

124. Gebel JM, Jr., Jauch EC, Brott TG, et al. Relative edema volume is a predictor of outcome in patients with hyperacute spontaneous intracerebral hemorrhage. Stroke 2002;33:2636-41.

125. Inaji M, Tomita H, Tone O, Tamaki M, Suzuki R, Ohno K. Chronological changes of perihematomal edema of human intracerebral hematoma. Acta Neurochir Suppl 2003;86:445-8.

126. Levine JM, Snider R, Finkelstein D, et al. Early edema in warfarin-related intracerebral hemorrhage. Neurocrit Care 2007;7:58-63.

127. Hua Y, Schallert T, Keep RF, Wu J, Hoff JT, Xi G. Behavioral tests after intracerebral hemorrhage in the rat. Stroke 2002;33:2478-84.

128. Gebel JM, Sila CA, Sloan MA, et al. Thrombolysis-related intracranial hemorrhage: a radiographic analysis of 244 cases from the GUSTO-1 trial with clinical correlation. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Stroke 1998;29:563-9.

129. Hua Y, Keep RF, Hoff JT, Xi G. Brain injury after intracerebral hemorrhage: the role of thrombin and iron. Stroke 2007;38:759-62.

130. Lee KR, Betz AL, Kim S, Keep RF, Hoff JT. The role of the coagulation cascade in brain edema formation after intracerebral hemorrhage. Acta Neurochir (Wien) 1996;138:396-400; discussion -1.

131. Nehls DG, Mendelow DA, Graham DI, Teasdale GM. Experimental intracerebral hemorrhage: early removal of a spontaneous mass lesion improves late outcome. Neurosurgery 1990;27:674-82; discussion 82.

132. Klatzo I. Presidental address. Neuropathological aspects of brain edema. J Neuropathol Exp Neurol 1967;26:1-14.

133. Simard JM, Kent TA, Chen M, Tarasov KV, Gerzanich V. Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications. Lancet Neurol 2007;6:258-68.

134. Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol 2006;1:223-36.

135. Doolittle ND, Abrey LE, Bleyer WA, et al. New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting. Clin Cancer Res 2005;11:421-8.

136. Schlageter KE, Molnar P, Lapin GD, Groothuis DR. Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties. Microvasc Res 1999;58:312-28.

137. McCarty JH. Cell biology of the neurovascular unit: implications for drug delivery across the blood-brain barrier. Assay Drug Dev Technol 2005;3:89-95.

138. Bloch O, Manley GT. The role of aquaporin-4 in cerebral water transport and edema. Neurosurg Focus 2007;22:E3.

139. Bondy C, Chin E, Smith BL, Preston GM, Agre P. Developmental gene expression and tissue distribution of the CHIP28 water-channel protein. Proc Natl Acad Sci U S A 1993;90:4500-4.

140. Manley GT, Fujimura M, Ma T, et al. Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke. Nat Med 2000;6:159-63.

141. Bloch O, Papadopoulos MC, Manley GT, Verkman AS. Aquaporin-4 gene deletion in mice increases focal edema associated with staphylococcal brain abscess. J Neurochem 2005;95:254-62.

142. Papadopoulos MC, Manley GT, Krishna S, Verkman AS. Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema. FASEB J 2004;18:1291-3.

References

166

143. Qing WG, Dong YQ, Ping TQ, et al. Brain edema after intracerebral hemorrhage in rats: the role of iron overload and aquaporin 4. J Neurosurg 2009;110:462-8.

144. Xue M, Del Bigio MR. Comparison of brain cell death and inflammatory reaction in three models of intracerebral hemorrhage in adult rats. J Stroke Cerebrovasc Dis 2003;12:152-9.

145. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-57.

146. Schweichel JU, Merker HJ. The morphology of various types of cell death in prenatal tissues. Teratology 1973;7:253-66.

147. Hotchkiss RS, Strasser A, McDunn JE, Swanson PE. Cell death. N Engl J Med 2009;361:1570-83.

148. Yakovlev AG, Faden AI. Mechanisms of neural cell death: implications for development of neuroprotective treatment strategies. NeuroRx 2004;1:5-16.

149. Hengartner MO, Ellis RE, Horvitz HR. Caenorhabditis elegans gene ced-9 protects cells from programmed cell death. Nature 1992;356:494-9.

150. Ellis HM, Horvitz HR. Genetic control of programmed cell death in the nematode C. elegans. Cell 1986;44:817-29.

151. Xue D, Shaham S, Horvitz HR. The Caenorhabditis elegans cell-death protein CED-3 is a cysteine protease with substrate specificities similar to those of the human CPP32 protease. Genes Dev 1996;10:1073-83.

152. Yuan J, Shaham S, Ledoux S, Ellis HM, Horvitz HR. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. Cell 1993;75:641-52.

153. Hengartner MO, Horvitz HR. C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2. Cell 1994;76:665-76.

154. Susin SA, Lorenzo HK, Zamzami N, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999;397:441-6.

155. Choi DW. Ischemia-induced neuronal apoptosis. Curr Opin Neurobiol 1996;6:667-72.

156. Niquet J, Seo DW, Wasterlain CG. Mitochondrial pathways of neuronal necrosis. Biochem Soc Trans 2006;34:1347-51.

157. Hail N, Jr., Carter BZ, Konopleva M, Andreeff M. Apoptosis effector mechanisms: a requiem performed in different keys. Apoptosis 2006;11:889-904.

158. Botto M, Walport MJ. C1q, autoimmunity and apoptosis. Immunobiology 2002;205:395-406.

159. Friedlander RM. Apoptosis and caspases in neurodegenerative diseases. N Engl J Med 2003;348:1365-75.

160. Simard JM, Chen M, Tarasov KV, et al. Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke. Nat Med 2006;12:433-40.

161. Gong C, Boulis N, Qian J, Turner DE, Hoff JT, Keep RF. Intracerebral hemorrhage-induced neuronal death. Neurosurgery 2001;48:875-82; discussion 82-3.

162. Hickenbottom SL, Grotta JC, Strong R, Denner LA, Aronowski J. Nuclear factor-kappaB and cell death after experimental intracerebral hemorrhage in rats. Stroke 1999;30:2472-7; discussion 7-8.

163. Felberg RA, Grotta JC, Shirzadi AL, et al. Cell death in experimental intracerebral hemorrhage: the "black hole" model of hemorrhagic damage. Ann Neurol 2002;51:517-24.

164. Matsushita K, Meng W, Wang X, et al. Evidence for apoptosis after intercerebral hemorrhage in rat striatum. J Cereb Blood Flow Metab 2000;20:396-404.

References

167

165. Qureshi AI, Suri MF, Ostrow PT, et al. Apoptosis as a form of cell death in intracerebral hemorrhage. Neurosurgery 2003;52:1041-7; discussion 7-8.

166. Qureshi AI, Ali Z, Suri MF, et al. Extracellular glutamate and other amino acids in experimental intracerebral hemorrhage: an in vivo microdialysis study. Crit Care Med 2003;31:1482-9.

167. Olney JW. Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science 1969;164:719-21.

168. Nilsson OG, Polito A, Saveland H, Ungerstedt U, Nordstrom CH. Are primary supratentorial intracerebral hemorrhages surrounded by a biochemical penumbra? A microdialysis study. Neurosurgery 2006;59:521-8; discussion -8.

169. Ardizzone TD, Lu A, Wagner KR, Tang Y, Ran R, Sharp FR. Glutamate receptor blockade attenuates glucose hypermetabolism in perihematomal brain after experimental intracerebral hemorrhage in rat. Stroke 2004;35:2587-91.

170. Lee ST, Chu K, Jung KH, et al. Memantine reduces hematoma expansion in experimental intracerebral hemorrhage, resulting in functional improvement. J Cereb Blood Flow Metab 2006;26:536-44.

171. Castillo J, Davalos A, Alvarez-Sabin J, et al. Molecular signatures of brain injury after intracerebral hemorrhage. Neurology 2002;58:624-9.

172. Wagner KR. Modeling intracerebral hemorrhage: glutamate, nuclear factor-kappa B signaling and cytokines. Stroke 2007;38:753-8.

173. Hossmann KA. Periinfarct depolarizations. Cerebrovasc Brain Metab Rev 1996;8:195-208.

174. Mun-Bryce S, Wilkerson AC, Papuashvili N, Okada YC. Recurring episodes of spreading depression are spontaneously elicited by an intracerebral hemorrhage in the swine. Brain Res 2001;888:248-55.

175. Kleinig TJ, Vink R. Suppression of inflammation in ischemic and hemorrhagic stroke: therapeutic options. Curr Opin Neurol 2009;22:294-301.

176. Trendelenburg G. Acute neurodegeneration and the inflammasome: central processor for danger signals and the inflammatory response? J Cereb Blood Flow Metab 2008;28:867-81.

177. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000;407:258-64.

178. de Garavilla L, Vergnolle N, Young SH, et al. Agonists of proteinase-activated receptor 1 induce plasma extravasation by a neurogenic mechanism. Br J Pharmacol 2001;133:975-87.

179. Luo W, Wang Y, Reiser G. Protease-activated receptors in the brain: Receptor expression, activation, and functions in neurodegeneration and neuroprotection. Brain Res Rev 2007.

180. Niclou S, Suidan HS, Brown-Luedi M, Monard D. Expression of the thrombin receptor mRNA in rat brain. Cell Mol Biol (Noisy-le-grand) 1994;40:421-8.

181. Striggow F, Riek-Burchardt M, Kiesel A, et al. Four different types of protease-activated receptors are widely expressed in the brain and are up-regulated in hippocampus by severe ischemia. Eur J Neurosci 2001;14:595-608.

182. Bartha K, Domotor E, Lanza F, Adam-Vizi V, Machovich R. Identification of thrombin receptors in rat brain capillary endothelial cells. J Cereb Blood Flow Metab 2000;20:175-82.

183. Junge CE, Lee CJ, Hubbard KB, et al. Protease-activated receptor-1 in human brain: localization and functional expression in astrocytes. Exp Neurol 2004;188:94-103.

184. Yamamoto C, Sugato M, Fujiwara Y, Kaji T. Selective promotion of plasminogen activator inhibitor-1 secretion by activation of proteinase-activated receptor-1 in cultured human brain microvascular pericytes: comparison with endothelial cells. Biol Pharm Bull 2005;28:208-11.

References

168

185. Arai T, Miklossy J, Klegeris A, Guo JP, McGeer PL. Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain. J Neuropathol Exp Neurol 2006;65:19-25.

186. Grammas P, Ottman T, Reimann-Philipp U, Larabee J, Weigel PH. Injured brain endothelial cells release neurotoxic thrombin. J Alzheimers Dis 2004;6:275-81.

187. Nishino A, Suzuki M, Ohtani H, et al. Thrombin may contribute to the pathophysiology of central nervous system injury. J Neurotrauma 1993;10:167-79.

188. Xue M, Del Bigio MR. Acute tissue damage after injections of thrombin and plasmin into rat striatum. Stroke 2001;32:2164-9.

189. Junge CE, Sugawara T, Mannaioni G, et al. The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia. Proc Natl Acad Sci U S A 2003;100:13019-24.

190. Hua Y, Wu J, Keep RF, Hoff JT, Xi G. Thrombin exacerbates brain edema in focal cerebral ischemia. Acta Neurochir Suppl 2003;86:163-6.

191. Cuomo O, Pignataro G, Gala R, et al. Antithrombin reduces ischemic volume, ameliorates neurologic deficits, and prolongs animal survival in both transient and permanent focal ischemia. Stroke 2007;38:3272-9.

192. Cannon JR, Hua Y, Richardson RJ, Xi G, Keep RF, Schallert T. The effect of thrombin on a 6-hydroxydopamine model of Parkinson's disease depends on timing. Behav Brain Res 2007;183:161-8.

193. Hamill CE, Caudle WM, Richardson JR, et al. Exacerbation of dopaminergic terminal damage in a mouse model of Parkinson's disease by the G-protein-coupled receptor protease-activated receptor 1. Mol Pharmacol 2007;72:653-64.

194. Kubo Y, Suzuki M, Kudo A, et al. Thrombin inhibitor ameliorates secondary damage in rat brain injury: suppression of inflammatory cells and vimentin-positive astrocytes. J Neurotrauma 2000;17:163-72.

195. Vaughan PJ, Pike CJ, Cotman CW, Cunningham DD. Thrombin receptor activation protects neurons and astrocytes from cell death produced by environmental insults. J Neurosci 1995;15:5389-401.

196. Masada T, Xi G, Hua Y, Keep RF. The effects of thrombin preconditioning on focal cerebral ischemia in rats. Brain Res 2000;867:173-9.

197. Hua Y, Keep RF, Hoff JT, Xi G. Thrombin preconditioning attenuates brain edema induced by erythrocytes and iron. J Cereb Blood Flow Metab 2003;23:1448-54.

198. Gidday JM. Cerebral preconditioning and ischaemic tolerance. Nat Rev Neurosci 2006;7:437-48.

199. Lee KR, Kawai N, Kim S, Sagher O, Hoff JT. Mechanisms of edema formation after intracerebral hemorrhage: effects of thrombin on cerebral blood flow, blood-brain barrier permeability, and cell survival in a rat model. J Neurosurg 1997;86:272-8.

200. Lee KR, Colon GP, Betz AL, Keep RF, Kim S, Hoff JT. Edema from intracerebral hemorrhage: the role of thrombin. J Neurosurg 1996;84:91-6.

201. Xue M, Fan Y, Liu S, Zygun DA, Demchuk A, Yong VW. Contributions of multiple proteases to neurotoxicity in a mouse model of intracerebral haemorrhage. Brain 2009;132:26-36.

202. Xue M, Hollenberg MD, Demchuk A, Yong VW. Relative importance of proteinase-activated receptor-1 versus matrix metalloproteinases in intracerebral hemorrhage-mediated neurotoxicity in mice. Stroke 2009;40:2199-204.

203. Rynkowski MA, Kim GH, Garrett MC, et al. C3a receptor antagonist attenuates brain injury after intracerebral hemorrhage. J Cereb Blood Flow Metab 2008.

204. Huber-Lang M, Sarma JV, Zetoune FS, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006;12:682-7.

References

169

205. Gong Y, Xi GH, Keep RF, Hoff JT, Hua Y. Complement inhibition attenuates brain edema and neurological deficits induced by thrombin. Acta Neurochir Suppl 2005;95:389-92.

206. Fujimoto S, Katsuki H, Ohnishi M, Takagi M, Kume T, Akaike A. Plasminogen potentiates thrombin cytotoxicity and contributes to pathology of intracerebral hemorrhage in rats. J Cereb Blood Flow Metab 2008;28:506-15.

207. Xi G, Keep RF, Hoff JT. Erythrocytes and delayed brain edema formation following intracerebral hemorrhage in rats. J Neurosurg 1998;89:991-6.

208. Xi G, Wagner KR, Keep RF, et al. Role of blood clot formation on early edema development after experimental intracerebral hemorrhage. Stroke 1998;29:2580-6.

209. Kitaoka T, Hua Y, Xi G, Hoff JT, Keep RF. Delayed argatroban treatment reduces edema in a rat model of intracerebral hemorrhage. Stroke 2002;33:3012-8.

210. Naval NS, Abdelhak TA, Urrunaga N, Zeballos P, Mirski MA, Carhuapoma JR. An association of prior statin use with decreased perihematomal edema. Neurocrit Care 2008;8:13-8.

211. FitzMaurice E, Wendell L, Snider R, et al. Effect of statins on intracerebral hemorrhage outcome and recurrence. Stroke 2008;39:2151-4.

212. Naval NS, Abdelhak TA, Zeballos P, Urrunaga N, Mirski MA, Carhuapoma JR. Prior statin use reduces mortality in intracerebral hemorrhage. Neurocrit Care 2008;8:6-12.

213. Serebruany VL, Miller M, Pokov AN, et al. Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study). Am J Cardiol 2006;97:1332-6.

214. Donovan FM, Pike CJ, Cotman CW, Cunningham DD. Thrombin induces apoptosis in cultured neurons and astrocytes via a pathway requiring tyrosine kinase and RhoA activities. J Neurosci 1997;17:5316-26.

215. Striggow F, Riek M, Breder J, Henrich-Noack P, Reymann KG, Reiser G. The protease thrombin is an endogenous mediator of hippocampal neuroprotection against ischemia at low concentrations but causes degeneration at high concentrations. Proc Natl Acad Sci U S A 2000;97:2264-9.

216. Rao HV, Thirumangalakudi L, Desmond P, Grammas P. Cyclin D1, cdk4, and Bim are involved in thrombin-induced apoptosis in cultured cortical neurons. J Neurochem 2007;101:498-505.

217. Xue M, Hollenberg MD, Yong VW. Combination of thrombin and matrix metalloproteinase-9 exacerbates neurotoxicity in cell culture and intracerebral hemorrhage in mice. J Neurosci 2006;26:10281-91.

218. Ramos-Mandujano G, Vazquez-Juarez E, Hernandez-Benitez R, Pasantes-Morales H. Thrombin potently enhances swelling-sensitive glutamate efflux from cultured astrocytes. Glia 2007;55:917-25.

219. Gingrich MB, Junge CE, Lyuboslavsky P, Traynelis SF. Potentiation of NMDA receptor function by the serine protease thrombin. J Neurosci 2000;20:4582-95.

220. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.

221. Wahlgren NG, Lindquist C. Haem derivatives in the cerebrospinal fluid after intracranial haemorrhage. Eur Neurol 1987;26:216-21.

222. Hua Y, Xi G, Keep RF, Hoff JT. Complement activation in the brain after experimental intracerebral hemorrhage. J Neurosurg 2000;92:1016-22.

223. Xi G, Hua Y, Bhasin RR, Ennis SR, Keep RF, Hoff JT. Mechanisms of edema formation after intracerebral hemorrhage: effects of extravasated red blood cells on blood flow and blood-brain barrier integrity. Stroke 2001;32:2932-8.

224. Wagner KR, Sharp FR, Ardizzone TD, Lu A, Clark JF. Heme and iron metabolism: role in cerebral hemorrhage. J Cereb Blood Flow Metab 2003;23:629-52.

References

170

225. Trakshel GM, Kutty RK, Maines MD. Resolution of the rat brain heme oxygenase activity: absence of a detectable amount of the inducible form (HO-1). Arch Biochem Biophys 1988;260:732-9.

226. Maines MD. Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J 1988;2:2557-68.

227. Cordonnier C, Al-Shahi Salman R, Wardlaw J. Spontaneous brain microbleeds: systematic review, subgroup analyses and standards for study design and reporting. Brain 2007;130:1988-2003.

228. Huang FP, Xi G, Keep RF, Hua Y, Nemoianu A, Hoff JT. Brain edema after experimental intracerebral hemorrhage: role of hemoglobin degradation products. J Neurosurg 2002;96:287-93.

229. Yang S, Hua Y, Nakamura T, Keep RF, Xi G. Up-regulation of brain ceruloplasmin in thrombin preconditioning. Acta Neurochir Suppl 2006;96:203-6.

230. Rosen AD, Frumin NV. Focal epileptogenesis after intracortical hemoglobin injection. Exp Neurol 1979;66:277-84.

231. Mehdiratta M, Kumar S, Hackney D, Schlaug G, Selim M. Association between serum ferritin level and perihematoma edema volume in patients with spontaneous intracerebral hemorrhage. Stroke 2008;39:1165-70.

232. Nakamura T, Xi G, Park JW, Hua Y, Hoff JT, Keep RF. Holo-transferrin and thrombin can interact to cause brain damage. Stroke 2005;36:348-52.

233. Nakamura T, Keep RF, Hua Y, Schallert T, Hoff JT, Xi G. Deferoxamine-induced attenuation of brain edema and neurological deficits in a rat model of intracerebral hemorrhage. Neurosurg Focus 2003;15:ECP4.

234. Wagner KR, Hua Y, de Courten-Myers GM, et al. Tin-mesoporphyrin, a potent heme oxygenase inhibitor, for treatment of intracerebral hemorrhage: in vivo and in vitro studies. Cell Mol Biol (Noisy-le-grand) 2000;46:597-608.

235. Koeppen AH, Dickson AC, Smith J. Heme oxygenase in experimental intracerebral hemorrhage: the benefit of tin-mesoporphyrin. J Neuropathol Exp Neurol 2004;63:587-97.

236. Wang J, Dore S. Heme oxygenase 2 deficiency increases brain swelling and inflammation after intracerebral hemorrhage. Neuroscience 2008;155:1133-41.

237. Qu Y, Chen-Roetling J, Benvenisti-Zarom L, Regan RF. Attenuation of oxidative injury after induction of experimental intracerebral hemorrhage in heme oxygenase-2 knockout mice. J Neurosurg 2007;106:428-35.

238. Regan RF, Panter SS. Hemoglobin potentiates excitotoxic injury in cortical cell culture. J Neurotrauma 1996;13:223-31.

239. Mendelow AD, Gregson BA, Fernandes HM, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 2005;365:387-97.

240. Participants NIW. Priorities for clinical research in intracerebral hemorrhage: report from a National Institute of Neurological Disorders and Stroke workshop. Stroke 2005;36:e23-41.

241. Rosell A, Ortega-Aznar A, Alvarez-Sabin J, et al. Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke 2006;37:1399-406.

242. Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke. J Neuroimmunol 2007;184:53-68.

243. Kane PJ, Modha P, Strachan RD, et al. The effect of immunosuppression on the development of cerebral oedema in an experimental model of intracerebral haemorrhage: whole body and regional irradiation. J Neurol Neurosurg Psychiatry 1992;55:781-6.

244. Aronowski J, Hall CE. New horizons for primary intracerebral hemorrhage treatment: experience from preclinical studies. Neurol Res 2005;27:268-79.

245. Wang J, Tsirka SE. Contribution of extracellular proteolysis and microglia to intracerebral hemorrhage. Neurocrit Care 2005;3:77-85.

References

171

246. Wang J, Rogove AD, Tsirka AE, Tsirka SE. Protective role of tuftsin fragment 1-3 in an animal model of intracerebral hemorrhage. Ann Neurol 2003;54:655-64.

247. Wang J, Dore S. Heme oxygenase-1 exacerbates early brain injury after intracerebral haemorrhage. Brain 2007;130:1643-52.

248. Lee MC, Heaney LM, Jacobson RL, Klassen AC. Cerebrospinal fluid in cerebral hemorrhage and infarction. Stroke 1975;6:638-41.

249. Titova E, Ostrowski RP, Kevil CG, et al. Reduced brain injury in CD18-deficient mice after experimental intracerebral hemorrhage. J Neurosci Res 2008;86:3240-5.

250. Peeling J, Del Bigio MR, Corbett D, Green AR, Jackson DM. Efficacy of disodium 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (NXY-059), a free radical trapping agent, in a rat model of hemorrhagic stroke. Neuropharmacology 2001;40:433-9.

251. Khalil M, Ronda J, Weintraub M, Jain K, Silver R, Silverman AJ. Brain mast cell relationship to neurovasculature during development. Brain Res 2007;1171:18-29.

252. Strbian D, Tatlisumak T, Ramadan UA, Lindsberg PJ. Mast cell blocking reduces brain edema and hematoma volume and improves outcome after experimental intracerebral hemorrhage. J Cereb Blood Flow Metab 2007;27:795-802.

253. Mattson MP, Meffert MK. Roles for NF-kappaB in nerve cell survival, plasticity, and disease. Cell Death Differ 2006;13:852-60.

254. Marsh BJ, Williams-Karnesky RL, Stenzel-Poore MP. Toll-like receptor signaling in endogenous neuroprotection and stroke. Neuroscience 2008.

255. Syeda F, Grosjean J, Houliston RA, et al. Cyclooxygenase-2 induction and prostacyclin release by protease-activated receptors in endothelial cells require cooperation between mitogen-activated protein kinase and NF-kappaB pathways. J Biol Chem 2006;281:11792-804.

256. Zhao X, Zhang Y, Strong R, Grotta JC, Aronowski J. 15d-Prostaglandin J2 activates peroxisome proliferator-activated receptor-gamma, promotes expression of catalase, and reduces inflammation, behavioral dysfunction, and neuronal loss after intracerebral hemorrhage in rats. J Cereb Blood Flow Metab 2006;26:811-20.

257. Masada T, Hua Y, Xi G, Yang GY, Hoff JT, Keep RF. Attenuation of intracerebral hemorrhage and thrombin-induced brain edema by overexpression of interleukin-1 receptor antagonist. J Neurosurg 2001;95:680-6.

258. Mayne M, Ni W, Yan HJ, et al. Antisense oligodeoxynucleotide inhibition of tumor necrosis factor-alpha expression is neuroprotective after intracerebral hemorrhage. Stroke 2001;32:240-8.

259. Hua Y, Wu J, Keep RF, Nakamura T, Hoff JT, Xi G. Tumor necrosis factor-alpha increases in the brain after intracerebral hemorrhage and thrombin stimulation. Neurosurgery 2006;58:542-50; discussion -50.

260. Chu K, Jeong SW, Jung KH, et al. Celecoxib induces functional recovery after intracerebral hemorrhage with reduction of brain edema and perihematomal cell death. J Cereb Blood Flow Metab 2004;24:926-33.

261. Xi G, Hua Y, Keep RF, Younger JG, Hoff JT. Brain edema after intracerebral hemorrhage: the effects of systemic complement depletion. Acta Neurochir Suppl 2002;81:253-6.

262. Ganea E, Trifan M, Laslo AC, Putina G, Cristescu C. Matrix metalloproteinases: useful and deleterious. Biochem Soc Trans 2007;35:689-91.

263. Zhao BQ, Tejima E, Lo EH. Neurovascular proteases in brain injury, hemorrhage and remodeling after stroke. Stroke 2007;38:748-52.

264. Rosenberg GA. Matrix metalloproteinases in neuroinflammation. Glia 2002;39:279-91.

265. Rosenberg GA, Navratil M. Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat. Neurology 1997;48:921-6.

References

172

266. Power C, Henry S, Del Bigio MR, et al. Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases. Ann Neurol 2003;53:731-42.

267. Alvarez-Sabin J, Delgado P, Abilleira S, et al. Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage: relationship to clinical and radiological outcome. Stroke 2004;35:1316-22.

268. Rosell A, Cuadrado E, Ortega-Aznar A, Hernandez-Guillamon M, Lo EH, Montaner J. MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke 2008;39:1121-6.

269. Grossetete M, Rosenberg GA. Matrix metalloproteinase inhibition facilitates cell death in intracerebral hemorrhage in mouse. J Cereb Blood Flow Metab 2008;28:752-63.

270. Tang J, Liu J, Zhou C, et al. Mmp-9 deficiency enhances collagenase-induced intracerebral hemorrhage and brain injury in mutant mice. J Cereb Blood Flow Metab 2004;24:1133-45.

271. Lee ST, Chu K, Jung KH, et al. Anti-inflammatory mechanism of intravascular neural stem cell transplantation in haemorrhagic stroke. Brain 2008;131:616-29.

272. Schwarting S, Litwak S, Hao W, Bahr M, Weise J, Neumann H. Hematopoietic stem cells reduce postischemic inflammation and ameliorate ischemic brain injury. Stroke 2008;39:2867-75.

273. Lekstrom-Himes JA, Gallin JI. Immunodeficiency diseases caused by defects in phagocytes. N Engl J Med 2000;343:1703-14.

274. Wu J, Hua Y, Keep RF, Schallert T, Hoff JT, Xi G. Oxidative brain injury from extravasated erythrocytes after intracerebral hemorrhage. Brain Res 2002;953:45-52.

275. Wagner KR, Packard BA, Hall CL, et al. Protein oxidation and heme oxygenase-1 induction in porcine white matter following intracerebral infusions of whole blood or plasma. Dev Neurosci 2002;24:154-60.

276. Wagner KR, Dean C, Beiler S, et al. Plasma infusions into porcine cerebral white matter induce early edema, oxidative stress, pro-inflammatory cytokine gene expression and DNA fragmentation: implications for white matter injury with increased blood-brain-barrier permeability. Curr Neurovasc Res 2005;2:149-55.

277. Mantle D, Siddique S, Eddeb F, Mendelow AD. Comparison of protein carbonyl and antioxidant levels in brain tissue from intracerebral haemorrhage and control cases. Clin Chim Acta 2001;312:185-90.

278. Nakamura T, Keep RF, Hua Y, Hoff JT, Xi G. Oxidative DNA injury after experimental intracerebral hemorrhage. Brain Res 2005;1039:30-6.

279. Nakamura T, Kuroda Y, Yamashita S, et al. Edaravone attenuates brain edema and neurologic deficits in a rat model of acute intracerebral hemorrhage. Stroke 2008;39:463-9.

280. Tang J, Liu J, Zhou C, et al. Role of NADPH oxidase in the brain injury of intracerebral hemorrhage. J Neurochem 2005;94:1342-50.

281. Hemmen TM, Lyden PD. Induced hypothermia for acute stroke. Stroke 2007;38:794-9.

282. Nussmeier NA. Management of temperature during and after cardiac surgery. Tex Heart Inst J 2005;32:472-6.

283. Shankaran S, Laptook AR, Ehrenkranz RA, et al. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. N Engl J Med 2005;353:1574-84.

284. Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med 2002;346:557-63.

285. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 2002;346:549-56.

286. Greer DM, Funk SE, Reaven NL, Ouzounelli M, Uman GC. Impact of fever on outcome in patients with stroke and neurologic injury: a comprehensive meta-analysis. Stroke 2008;39:3029-35.

References

173

287. Wagner KR, Beiler S, Beiler C, et al. Delayed profound local brain hypothermia markedly reduces interleukin-1beta gene expression and vasogenic edema development in a porcine model of intracerebral hemorrhage. Acta Neurochir Suppl 2006;96:177-82.

288. Kawanishi M, Kawai N, Nakamura T, Luo C, Tamiya T, Nagao S. Effect of delayed mild brain hypothermia on edema formation after intracerebral hemorrhage in rats. J Stroke Cerebrovasc Dis 2008;17:187-95.

289. MacLellan CL, Davies LM, Fingas MS, Colbourne F. The influence of hypothermia on outcome after intracerebral hemorrhage in rats. Stroke 2006;37:1266-70.

290. Fingas M, Clark DL, Colbourne F. The effects of selective brain hypothermia on intracerebral hemorrhage in rats. Exp Neurol 2007.

291. den Hertog HM, van der Worp HB, van Gemert HM, et al. The Paracetamol (Acetaminophen) In Stroke (PAIS) trial: a multicentre, randomised, placebo-controlled, phase III trial. Lancet Neurol 2009;8:434-40.

292. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005;352:777-85.

293. Friederich PW, Henny CP, Messelink EJ, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003;361:201-5.

294. Lapchak PA, Araujo DM. Advances in hemorrhagic stroke therapy: conventional and novel approaches. Expert Opin Emerg Drugs 2007;12:389-406.

295. Mayer SA, Davis SM, Skolnick BE, et al. Can a subset of intracerebral hemorrhage patients benefit from hemostatic therapy with recombinant activated factor VII? Stroke 2009;40:833-40.

296. Anderson CS, Huang Y, Wang JG, et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol 2008;7:391-9.

297. Misra UK, Kalita J, Ranjan P, Mandal SK. Mannitol in intracerebral hemorrhage: a randomized controlled study. J Neurol Sci 2005;234:41-5.

298. Fernandes HM, Siddique S, Banister K, et al. Continuous monitoring of ICP and CPP following ICH and its relationship to clinical, radiological and surgical parameters. Acta Neurochir Suppl 2000;76:463-6.

299. Qureshi AI, Geocadin RG, Suarez JI, Ulatowski JA. Long-term outcome after medical reversal of transtentorial herniation in patients with supratentorial mass lesions. Crit Care Med 2000;28:1556-64.

300. Matsuoka H, Hamada R. Role of thrombin in CNS damage associated with intracerebral haemorrhage: opportunity for pharmacological intervention? CNS Drugs 2002;16:509-16.

301. Lyden PD, Shuaib A, Lees KR, et al. Safety and tolerability of NXY-059 for acute intracerebral hemorrhage: the CHANT Trial. Stroke 2007;38:2262-9.

302. Ziai WC, Port JD, Cowan JA, Garonzik IM, Bhardwaj A, Rigamonti D. Decompressive craniectomy for intractable cerebral edema: experience of a single center. J Neurosurg Anesthesiol 2003;15:25-32.

303. Mendelow AD, Unterberg A. Surgical treatment of intracerebral haemorrhage. Curr Opin Crit Care 2007;13:169-74.

304. Broderick J, Connolly S, Feldmann E, et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke 2007;38:2001-23.

305. Dierssen G, Carda R, Coca JM. The influence of large decompressive craniectomy on the outcome of surgical treatment in spontaneous intracerebral haematomas. Acta Neurochir (Wien) 1983;69:53-60.

306. Murthy JM, Chowdary GV, Murthy TV, Bhasha PS, Naryanan TJ. Decompressive craniectomy with clot evacuation in large hemispheric hypertensive intracerebral hemorrhage. Neurocrit Care 2005;2:258-62.

References

174

307. Naval NS, Nyquist P, Carhuapoma JR. ICH aspiration and thrombolysis. J Neurol Sci 2007;261:80-3.

308. Auer LM, Deinsberger W, Niederkorn K, et al. Endoscopic surgery versus medical treatment for spontaneous intracerebral hematoma: a randomized study. J Neurosurg 1989;70:530-5.

309. Hattori N, Katayama Y, Maya Y, Gatherer A. Impact of stereotactic hematoma evacuation on activities of daily living during the chronic period following spontaneous putaminal hemorrhage: a randomized study. J Neurosurg 2004;101:417-20.

310. Teernstra OP, Evers SM, Lodder J, Leffers P, Franke CL, Blaauw G. Stereotactic treatment of intracerebral hematoma by means of a plasminogen activator: a multicenter randomized controlled trial (SICHPA). Stroke 2003;34:968-74.

311. Wagner KR, Xi G, Hua Y, et al. Ultra-early clot aspiration after lysis with tissue plasminogen activator in a porcine model of intracerebral hemorrhage: edema reduction and blood-brain barrier protection. J Neurosurg 1999;90:491-8.

312. Thiex R, Kuker W, Muller HD, et al. The long-term effect of recombinant tissue-plasminogen-activator (rt-PA) on edema formation in a large-animal model of intracerebral hemorrhage. Neurol Res 2003;25:254-62.

313. Rohde V, Rohde I, Thiex R, et al. Fibrinolysis therapy achieved with tissue plasminogen activator and aspiration of the liquefied clot after experimental intracerebral hemorrhage: rapid reduction in hematoma volume but intensification of delayed edema formation. J Neurosurg 2002;97:954-62.

314. Kaur J, Zhao Z, Klein GM, Lo EH, Buchan AM. The neurotoxicity of tissue plasminogen activator? J Cereb Blood Flow Metab 2004;24:945-63.

315. Naff NJ, Hanley DF, Keyl PM, et al. Intraventricular thrombolysis speeds blood clot resolution: results of a pilot, prospective, randomized, double-blind, controlled trial. Neurosurgery 2004;54:577-83; discussion 83-4.

316. Zhang Z, Li X, Liu Y, Shao Y, Xu S, Yang Y. Application of neuroendoscopy in the treatment of intraventricular hemorrhage. Cerebrovasc Dis 2007;24:91-6.

317. Von Euler US, Gaddum JH. An unidentified depressor substance in certain tissue extracts. J Physiol 1931;72:74-87.

318. Pernow B. Studies on substance P; purification, occurrence and biological actions. Acta Physiol Scand Suppl 1953;29:1-89.

319. Chang MM, Leeman SE, Niall HD. Amino-acid sequence of substance P. Nat New Biol 1971;232:86-7.

320. Nawa H, Kotani H, Nakanishi S. Tissue-specific generation of two preprotachykinin mRNAs from one gene by alternative RNA splicing. Nature 1984;312:729-34.

321. Page NM, Bell NJ, Gardiner SM, et al. Characterization of the endokinins: human tachykinins with cardiovascular activity. Proc Natl Acad Sci U S A 2003;100:6245-50.

322. Zhang Y, Lu L, Furlonger C, Wu GE, Paige CJ. Hemokinin is a hematopoietic-specific tachykinin that regulates B lymphopoiesis. Nat Immunol 2000;1:392-7.

323. Carter MS, Krause JE. Structure, expression, and some regulatory mechanisms of the rat preprotachykinin gene encoding substance P, neurokinin A, neuropeptide K, and neuropeptide gamma. J Neurosci 1990;10:2203-14.

324. Takeda Y, Takeda J, Smart BM, Krause JE. Regional distribution of neuropeptide gamma and other tachykinin peptides derived from the substance P gene in the rat. Regul Pept 1990;28:323-33.

325. Harmar AJ, Hyde V, Chapman K. Identification and cDNA sequence of delta-preprotachykinin, a fourth splicing variant of the rat substance P precursor. FEBS Lett 1990;275:22-4.

326. Hokfelt T, Pernow B, Wahren J. Substance P: a pioneer amongst neuropeptides. J Intern Med 2001;249:27-40.

327. Harrison S, Geppetti P. Substance p. Int J Biochem Cell Biol 2001;33:555-76.

References

175

328. Donaldson LF, Haskell CA, Hanley MR. Functional characterization by heterologous expression of a novel cloned tachykinin peptide receptor. Biochem J 1996;320 ( Pt 1):1-5.

329. Pinto FM, Almeida TA, Hernandez M, Devillier P, Advenier C, Candenas ML. mRNA expression of tachykinins and tachykinin receptors in different human tissues. Eur J Pharmacol 2004;494:233-9.

330. Quartara L, Maggi CA. The tachykinin NK1 receptor. Part I: ligands and mechanisms of cellular activation. Neuropeptides 1997;31:537-63.

331. Castro-Obregon S, Rao RV, del Rio G, et al. Alternative, nonapoptotic programmed cell death: mediation by arrestin 2, ERK2, and Nur77. J Biol Chem 2004;279:17543-53.

332. Fong TM, Anderson SA, Yu H, Huang RR, Strader CD. Differential activation of intracellular effector by two isoforms of human neurokinin-1 receptor. Mol Pharmacol 1992;41:24-30.

333. Lai JP, Cnaan A, Zhao H, Douglas SD. Detection of full-length and truncated neurokinin-1 receptor mRNA expression in human brain regions. J Neurosci Methods 2008;168:127-33.

334. Bowden JJ, Garland AM, Baluk P, et al. Direct observation of substance P-induced internalization of neurokinin 1 (NK1) receptors at sites of inflammation. Proc Natl Acad Sci U S A 1994;91:8964-8.

335. Defea K, Schmidlin F, Dery O, Grady EF, Bunnett NW. Mechanisms of initiation and termination of signalling by neuropeptide receptors: a comparison with the proteinase-activated receptors. Biochem Soc Trans 2000;28:419-26.

336. Li H, Leeman SE, Slack BE, et al. A substance P (neurokinin-1) receptor mutant carboxyl-terminally truncated to resemble a naturally occurring receptor isoform displays enhanced responsiveness and resistance to desensitization. Proc Natl Acad Sci U S A 1997;94:9475-80.

337. Brodin E, Gazelius B, Lundberg JM, Olgart L. Substance P in trigeminal nerve endings: occurrence and release. Acta Physiol Scand 1981;111:501-3.

338. Lecci A, Giuliani S, Tramontana M, Carini F, Maggi CA. Peripheral actions of tachykinins. Neuropeptides 2000;34:303-13.

339. Jones S, Tucker KL, Sage T, et al. Peripheral tachykinins and the neurokinin receptor NK1 are required for platelet thrombus formation. Blood 2008;111:605-12.

340. Hamel R, Ford-Hutchinson AW, Blazejczak C, Van den Brekel A. Tachykinin involvement in cutaneous anaphylaxis in the guinea pig. Can J Physiol Pharmacol 1988;66:1361-7.

341. Green PG. Gastrin-releasing peptide, substance P and cytokines in rheumatoid arthritis. Arthritis Res Ther 2005;7:111-3.

342. Gross KJ, Pothoulakis C. Role of neuropeptides in inflammatory bowel disease. Inflamm Bowel Dis 2007;13:918-32.

343. Mazzone SB. Targeting tachykinins for the treatment of obstructive airways disease. Treat Respir Med 2004;3:201-16.

344. Roosterman D, Goerge T, Schneider SW, Bunnett NW, Steinhoff M. Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. Physiol Rev 2006;86:1309-79.

345. Skofitsch G, Jacobowitz DM. Calcitonin gene-related peptide coexists with substance P in capsaicin sensitive neurons and sensory ganglia of the rat. Peptides 1985;6:747-54.

346. Dalsgaard CJ, Haegerstrand A, Theodorsson-Norheim E, Brodin E, Hokfelt T. Neurokinin A-like immunoreactivity in rat primary sensory neurons; coexistence with substance P. Histochemistry 1985;83:37-9.

347. Saria A, Gamse R, Petermann J, Fischer JA, Theodorsson-Norheim E, Lundberg JM. Simultaneous release of several tachykinins and calcitonin gene-related peptide from rat spinal cord slices. Neurosci Lett 1986;63:310-4.

References

176

348. Hanko J, Hardebo JE, Kahrstrom J, Owman C, Sundler F. Calcitonin gene-related peptide is present in mammalian cerebrovascular nerve fibres and dilates pial and peripheral arteries. Neurosci Lett 1985;57:91-5.

349. Hua X, Lundberg JM, Theodorsson-Norheim E, Brodin E. Comparison of cardiovascular and bronchoconstrictor effects of substance P, substance K and other tachykinins. Naunyn Schmiedebergs Arch Pharmacol 1984;328:196-201.

350. Gamse R, Saria A. Potentiation of tachykinin-induced plasma protein extravasation by calcitonin gene-related peptide. Eur J Pharmacol 1985;114:61-6.

351. McDonald DM. Endothelial gaps and permeability of venules in rat tracheas exposed to inflammatory stimuli. Am J Physiol 1994;266:L61-83.

352. Baluk P, Hirata A, Thurston G, et al. Endothelial gaps: time course of formation and closure in inflamed venules of rats. Am J Physiol 1997;272:L155-70.

353. McDonald DM, Thurston G, Baluk P. Endothelial gaps as sites for plasma leakage in inflammation. Microcirculation 1999;6:7-22.

354. Tominaga M, Caterina MJ, Malmberg AB, et al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 1998;21:531-43.

355. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997;389:816-24.

356. Steinhoff M, Vergnolle N, Young SH, et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 2000;6:151-8.

357. Geppetti P. Sensory neuropeptide release by bradykinin: mechanisms and pathophysiological implications. Regul Pept 1993;47:1-23.

358. Richardson JD, Vasko MR. Cellular mechanisms of neurogenic inflammation. J Pharmacol Exp Ther 2002;302:839-45.

359. Szallasi A, Blumberg PM. Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev 1999;51:159-212.

360. Singh Tahim A, Santha P, Nagy I. Inflammatory mediators convert anandamide into a potent activator of the vanilloid type 1 transient receptor potential receptor in nociceptive primary sensory neurons. Neuroscience 2005;136:539-48.

361. Nicol GD, Lopshire JC, Pafford CM. Tumor necrosis factor enhances the capsaicin sensitivity of rat sensory neurons. J Neurosci 1997;17:975-82.

362. Plant TD, Zollner C, Kepura F, et al. Endothelin potentiates TRPV1 via ETA receptor-mediated activation of protein kinase C. Mol Pain 2007;3:35.

363. Cortright DN, Szallasi A. Biochemical pharmacology of the vanilloid receptor TRPV1. An update. Eur J Biochem 2004;271:1814-9.

364. Liang YF, Haake B, Reeh PW. Sustained sensitization and recruitment of rat cutaneous nociceptors by bradykinin and a novel theory of its excitatory action. J Physiol 2001;532:229-39.

365. Cao T, Gerard NP, Brain SD. Use of NK(1) knockout mice to analyze substance P-induced edema formation. Am J Physiol 1999;277:R476-81.

366. Lau AH, Chow SS, Ng YS. Immunologically induced histamine release from rat peritoneal mast cells is enhanced by low levels of substance P. Eur J Pharmacol 2001;414:295-303.

367. Kulka M, Sheen CH, Tancowny BP, Grammer LC, Schleimer RP. Neuropeptides activate human mast cell degranulation and chemokine production. Immunology 2008;123:398-410.

References

177

368. Saria A, Lundberg JM, Skofitsch G, Lembeck F. Vascular protein linkage in various tissue induced by substance P, capsaicin, bradykinin, serotonin, histamine and by antigen challenge. Naunyn Schmiedebergs Arch Pharmacol 1983;324:212-8.

369. Brain SD, Williams TJ. Interactions between the tachykinins and calcitonin gene-related peptide lead to the modulation of oedema formation and blood flow in rat skin. Br J Pharmacol 1989;97:77-82.

370. Naukkarinen A, Harvima IT, Aalto ML, Horsmanheimo M. Mast cell tryptase and chymase are potential regulators of neurogenic inflammation in psoriatic skin. Int J Dermatol 1994;33:361-6.

371. Zimmerman BJ, Anderson DC, Granger DN. Neuropeptides promote neutrophil adherence to endothelial cell monolayers. Am J Physiol 1992;263:G678-82.

372. Dianzani C, Collino M, Lombardi G, Garbarino G, Fantozzi R. Substance P increases neutrophil adhesion to human umbilical vein endothelial cells. Br J Pharmacol 2003;139:1103-10.

373. Iwamoto I, Tomoe S, Tomioka H, Yoshida S. Substance P-induced granulocyte infiltration in mouse skin: the mast cell-dependent granulocyte infiltration by the N-terminal peptide is enhanced by the activation of vascular endothelial cells by the C-terminal peptide. Clin Exp Immunol 1992;87:203-7.

374. Cao T, Pinter E, Al-Rashed S, Gerard N, Hoult JR, Brain SD. Neurokinin-1 receptor agonists are involved in mediating neutrophil accumulation in the inflamed, but not normal, cutaneous microvasculature: an in vivo study using neurokinin-1 receptor knockout mice. J Immunol 2000;164:5424-9.

375. Pinter E, Brown B, Hoult JR, Brain SD. Lack of evidence for tachykinin NK1 receptor-mediated neutrophil accumulation in the rat cutaneous microvasculature by thermal injury. Eur J Pharmacol 1999;369:91-8.

376. Costa SK, Yshii LM, Poston RN, Muscara MN, Brain SD. Pivotal role of endogenous tachykinins and the NK1 receptor in mediating leukocyte accumulation, in the absence of oedema formation, in response to TNFalpha in the cutaneous microvasculature. J Neuroimmunol 2006;171:99-109.

377. Bozic CR, Lu B, Hopken UE, Gerard C, Gerard NP. Neurogenic amplification of immune complex inflammation. Science 1996;273:1722-5.

378. Ahluwalia A, De Felipe C, O'Brien J, Hunt SP, Perretti M. Impaired IL-1beta-induced neutrophil accumulation in tachykinin NK1 receptor knockout mice. Br J Pharmacol 1998;124:1013-5.

379. Quinlan KL, Naik SM, Cannon G, et al. Substance P activates coincident NF-AT- and NF-kappa B-dependent adhesion molecule gene expression in microvascular endothelial cells through intracellular calcium mobilization. J Immunol 1999;163:5656-65.

380. Chernova I, Lai JP, Li H, et al. Substance P (SP) enhances CCL5-induced chemotaxis and intracellular signaling in human monocytes, which express the truncated neurokinin-1 receptor (NK1R). J Leukoc Biol 2009;85:154-64.

381. Hood VC, Cruwys SC, Urban L, Kidd BL. Differential role of neurokinin receptors in human lymphocyte and monocyte chemotaxis. Regul Pept 2000;96:17-21.

382. Okabe T, Hide M, Koro O, Yamamoto S. Substance P induces tumor necrosis factor-alpha release from human skin via mitogen-activated protein kinase. Eur J Pharmacol 2000;398:309-15.

383. Ho WZ, Kaufman D, Uvaydova M, Douglas SD. Substance P augments interleukin-10 and tumor necrosis factor-alpha release by human cord blood monocytes and macrophages. J Neuroimmunol 1996;71:73-80.

384. Gallicchio M, Benetti E, Rosa AC, Fantozzi R. Tachykinin receptor modulation of cyclooxygenase-2 expression in human polymorphonuclear leucocytes. Br J Pharmacol 2009;156:486-96.

385. Brunelleschi S, Parenti A, Ceni E, Giotti A, Fantozzi R. Enhanced responsiveness of ovalbumin-sensitized guinea-pig alveolar macrophages to tachykinins. Br J Pharmacol 1992;107:964-9.

References

178

386. Wozniak A, McLennan G, Betts WH, Murphy GA, Scicchitano R. Activation of human neutrophils by substance P: effect on FMLP-stimulated oxidative and arachidonic acid metabolism and on antibody-dependent cell-mediated cytotoxicity. Immunology 1989;68:359-64.

387. Sterner-Kock A, Braun RK, van der Vliet A, et al. Substance P primes the formation of hydrogen peroxide and nitric oxide in human neutrophils. J Leukoc Biol 1999;65:834-40.

388. Hafstrom I, Gyllenhammar H, Palmblad J, Ringertz B. Substance P activates and modulates neutrophil oxidative metabolism and aggregation. J Rheumatol 1989;16:1033-7.

389. Sun J, Ramnath RD, Zhi L, Tamizhselvi R, Bhatia M. Substance P enhances NF-kappaB transactivation and chemokine response in murine macrophages via ERK1/2 and p38 MAPK signaling pathways. Am J Physiol Cell Physiol 2008;294:C1586-96.

390. Marriott I, Bost KL. Substance P diminishes lipopolysaccharide and interferon-gamma-induced TGF-beta 1 production by cultured murine macrophages. Cell Immunol 1998;183:113-20.

391. Page NM. Hemokinins and endokinins. Cell Mol Life Sci 2004;61:1652-63.

392. Ho WZ, Lai JP, Zhu XH, Uvaydova M, Douglas SD. Human monocytes and macrophages express substance P and neurokinin-1 receptor. J Immunol 1997;159:5654-60.

393. Lai JP, Douglas SD, Ho WZ. Human lymphocytes express substance P and its receptor. J Neuroimmunol 1998;86:80-6.

394. Moriarty D, Selve N, Baird AW, Goldhill J. Potent NK1 antagonism by SR-140333 reduces rat colonic secretory response to immunocyte activation. Am J Physiol Cell Physiol 2001;280:C852-8.

395. Hurd YL, Keller E, Sotonyi P, Sedvall G. Preprotachykinin-A mRNA expression in the human and monkey brain: An in situ hybridization study. J Comp Neurol 1999;411:56-72.

396. Uddman R, Edvinsson L, Owman C, Sundler F. Perivascular substance P: occurrence and distribution in mammalian pial vessels. J Cereb Blood Flow Metab 1981;1:227-32.

397. Chappa AK, Audus KL, Lunte SM. Characteristics of substance P transport across the blood-brain barrier. Pharm Res 2006;23:1201-8.

398. Freed AL, Audus KL, Lunte SM. Investigation of substance P transport across the blood-brain barrier. Peptides 2002;23:157-65.

399. Annunziata P, Cioni C, Santonini R, Paccagnini E. Substance P antagonist blocks leakage and reduces activation of cytokine-stimulated rat brain endothelium. J Neuroimmunol 2002;131:41-9.

400. Lai JP, Douglas SD, Shaheen F, Pleasure DE, Ho WZ. Quantification of substance p mRNA in human immune cells by real-time reverse transcriptase PCR assay. Clin Diagn Lab Immunol 2002;9:138-43.

401. Leone C, Le Pavec G, Meme W, et al. Characterization of human monocyte-derived microglia-like cells. Glia 2006;54:183-92.

402. Michel JP, Sakamoto N, Bouvier R, Tommasi M, Pearson J. Substance P-immunoreactive astrocytes related to deep white matter and striatal blood vessels in human brain. Brain Res 1986;377:383-7.

403. Too HP, Marriott DR, Wilkin GP. Preprotachykinin-A and substance P receptor (NK1) gene expression in rat astrocytes in vitro. Neurosci Lett 1994;182:185-7.

404. Lin RC. Reactive astrocytes express substance-P immunoreactivity in the adult forebrain after injury. Neuroreport 1995;7:310-2.

405. Hasenohrl RU, Souza-Silva MA, Nikolaus S, et al. Substance P and its role in neural mechanisms governing learning, anxiety and functional recovery. Neuropeptides 2000;34:272-80.

406. Herpfer I, Lieb K. Substance P and Substance P receptor antagonists in the pathogenesis and treatment of affective disorders. World J Biol Psychiatry 2003;4:56-63.

References

179

407. Beaujouan JC, Torrens Y, Saffroy M, Kemel ML, Glowinski J. A 25 year adventure in the field of tachykinins. Peptides 2004;25:339-57.

408. Lembeck F. Zur Frage der zentralen Ubertragung afferenter Impulse III. Mitteilung. Das Vorkommen und die Bedeutung der Substanz P in den dorsalen Wurzeln des Ruckenmarks. Naunyn-Schmiedeberg's Arch Pharmacol 1953;219.

409. Zubrzycka M, Janecka A. Substance P: transmitter of nociception (Minireview). Endocr Regul 2000;34:195-201.

410. Ikoma A, Steinhoff M, Stander S, Yosipovitch G, Schmelz M. The neurobiology of itch. Nat Rev Neurosci 2006;7:535-47.

411. Prommer E. Aprepitant (EMEND): the role of substance P in nausea and vomiting. J Pain Palliat Care Pharmacother 2005;19:31-9.

412. de Mos M, Huygen FJ, Stricker BH, Dieleman JP, Sturkenboom MC. The association between ACE inhibitors and the complex regional pain syndrome: Suggestions for a neuro-inflammatory pathogenesis of CRPS. Pain 2009;142:218-24.

413. Li L, Gao X, Zhao J, Ji X, Wei H, Luo Y. Plasma and cerebrospinal fluid substance P in post-stroke patients with depression. Psychiatry Clin Neurosci 2009;63:298-304.

414. Herpfer I, Lieb K. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential. CNS Drugs 2005;19:275-93.

415. Moskowitz MA. Pathophysiology of headache--past and present. Headache 2007;47 Suppl 1:S58-63.

416. Liu H, Cao Y, Basbaum AI, Mazarati AM, Sankar R, Wasterlain CG. Resistance to excitotoxin-induced seizures and neuronal death in mice lacking the preprotachykinin A gene. Proc Natl Acad Sci U S A 1999;96:12096-101.

417. Castro-Obregon S, Del Rio G, Chen SF, et al. A ligand-receptor pair that triggers a non-apoptotic form of programmed cell death. Cell Death Differ 2002;9:807-17.

418. Zhu J, Xu W, Wang J, Ali SF, Angulo JA. The Neurokinin-1 Receptor Modulates the Methamphetamine-Induced Striatal Apoptosis and Nitric Oxide Formation in Mice. J Neurochem 2009.

419. Pieri M, Amadoro G, Carunchio I, et al. SP protects cerebellar granule cells against beta-amyloid-induced apoptosis by down-regulation and reduced activity of Kv4 potassium channels. Neuropharmacology 2009.

420. Marriott I. The role of tachykinins in central nervous system inflammatory responses. Front Biosci 2004;9:2153-65.

421. Nessler S, Stadelmann C, Bittner A, et al. Suppression of autoimmune encephalomyelitis by a neurokinin-1 receptor antagonist--a putative role for substance P in CNS inflammation. J Neuroimmunol 2006;179:1-8.

422. Kennedy PG, Rodgers J, Jennings FW, Murray M, Leeman SE, Burke JM. A substance P antagonist, RP-67,580, ameliorates a mouse meningoencephalitic response to Trypanosoma brucei brucei. Proc Natl Acad Sci U S A 1997;94:4167-70.

423. Liao CW, Cho WL, Kao TC, Su KE, Lin YH, Fan CK. Blood-brain barrier impairment with enhanced SP, NK-1R, GFAP and claudin-5 expressions in experimental cerebral toxocariasis. Parasite Immunol 2008;30:525-34.

424. Chen LW, Yung KK, Chan YS. Neurokinin peptides and neurokinin receptors as potential therapeutic intervention targets of basal ganglia in the prevention and treatment of Parkinson's disease. Curr Drug Targets 2004;5:197-206.

425. Ho WZ, Douglas SD. Substance P and neurokinin-1 receptor modulation of HIV. J Neuroimmunol 2004;157:48-55.

References

180

426. Ansar S, Svendgaard NA, Edvinsson L. Neurokinin-1 receptor antagonism in a rat model of subarachnoid hemorrhage: prevention of upregulation of contractile ETB and 5-HT1B receptors and cerebral blood flow reduction. J Neurosurg 2007;106:881-6.

427. Turner R, Vink R. Inhibition of neurogenic inflammation as a novel treatment for ischemic stroke. Drug News Perspect 2007;20:221-6.

428. Donkin JJ, Turner RJ, Hassan I, Vink R. Substance P in traumatic brain injury. Prog Brain Res 2007;161:97-109.

429. Vink R, Young A, Bennett CJ, et al. Neuropeptide release influences brain edema formation after diffuse traumatic brain injury. Acta Neurochir Suppl 2003;86:257-60.

430. Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. J Neurosci 1987;7:4129-36.

431. Toneatto S, Finco O, van der Putten H, Abrignani S, Annunziata P. Evidence of blood-brain barrier alteration and activation in HIV-1 gp120 transgenic mice. Aids 1999;13:2343-8.

432. Chauhan VS, Sterka DG, Jr., Gray DL, Bost KL, Marriott I. Neurogenic exacerbation of microglial and astrocyte responses to Neisseria meningitidis and Borrelia burgdorferi. J Immunol 2008;180:8241-9.

433. Reinke EK, Johnson MJ, Ling C, et al. Substance P receptor mediated maintenance of chronic inflammation in EAE. J Neuroimmunol 2006;180:117-25.

434. Kostyk SK, Kowall NW, Hauser SL. Substance P immunoreactive astrocytes are present in multiple sclerosis plaques. Brain Res 1989;504:284-8.

435. Hu DE, Easton AS, Fraser PA. TRPV1 activation results in disruption of the blood-brain barrier in the rat. Br J Pharmacol 2005;146:576-84.

436. Turner RJ, Blumbergs PC, Sims NR, Helps SC, Rodgers KM, Vink R. Increased substance P immunoreactivity and edema formation following reversible ischemic stroke. Acta Neurochir Suppl 2006;96:263-6.

437. Sharma HS, Nyberg F, Olsson Y, Dey PK. Alteration of substance P after trauma to the spinal cord: an experimental study in the rat. Neuroscience 1990;38:205-12.

438. Kim SR, Chung YC, Chung ES, et al. Roles of transient receptor potential vanilloid subtype 1 and cannabinoid type 1 receptors in the brain: neuroprotection versus neurotoxicity. Mol Neurobiol 2007;35:245-54.

439. Zygmunt PM, Petersson J, Andersson DA, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999;400:452-7.

440. Huang SM, Bisogno T, Trevisani M, et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci U S A 2002;99:8400-5.

441. Cernak I, Vink R, Natale J, et al. The "dark side" of endocannabinoids: a neurotoxic role for anandamide. J Cereb Blood Flow Metab 2004;24:564-78.

442. Rasley A, Bost KL, Olson JK, Miller SD, Marriott I. Expression of functional NK-1 receptors in murine microglia. Glia 2002;37:258-67.

443. Beaujouan JC, Teutsch B, Saffroy M, Petitet F, Torrens Y, Glowinski J. NK-1 receptors are the only class of tachykinin receptors found on mouse cortical astrocytes. Peptides 1991;12:813-20.

444. Lai JP, Douglas SD, Wang YJ, Ho WZ. Real-time reverse transcription-PCR quantitation of substance P receptor (NK-1R) mRNA. Clin Diagn Lab Immunol 2005;12:537-41.

445. Stumm R, Culmsee C, Schafer MK, Krieglstein J, Weihe E. Adaptive plasticity in tachykinin and tachykinin receptor expression after focal cerebral ischemia is differentially linked to gabaergic and glutamatergic cerebrocortical circuits and cerebrovenular endothelium. J Neurosci 2001;21:798-811.

References

181

446. Tanabe T, Otani H, Bao L, et al. Intracellular signaling pathway of substance P-induced superoxide production in human neutrophils. Eur J Pharmacol 1996;299:187-95.

447. Giulian D, Corpuz M, Richmond B, Wendt E, Hall ER. Activated microglia are the principal glial source of thromboxane in the central nervous system. Neurochem Int 1996;29:65-76.

448. Block ML, Li G, Qin L, et al. Potent regulation of microglia-derived oxidative stress and dopaminergic neuron survival: substance P vs. dynorphin. Faseb J 2006;20:251-8.

449. Martin FC, Charles AC, Sanderson MJ, Merrill JE. Substance P stimulates IL-1 production by astrocytes via intracellular calcium. Brain Res 1992;599:13-8.

450. Guo CJ, Douglas SD, Gao Z, et al. Interleukin-1beta upregulates functional expression of neurokinin-1 receptor (NK-1R) via NF-kappaB in astrocytes. Glia 2004;48:259-66.

451. Martin FC, Anton PA, Gornbein JA, Shanahan F, Merrill JE. Production of interleukin-1 by microglia in response to substance P: role for a non-classical NK-1 receptor. J Neuroimmunol 1993;42:53-60.

452. Skidgel RA, Erdos EG. Angiotensin converting enzyme (ACE) and neprilysin hydrolyze neuropeptides: a brief history, the beginning and follow-ups to early studies. Peptides 2004;25:521-5.

453. Brecher P, Tercyak A, Gavras H, Chobanian AV. Peptidyl dipeptidase in rabbit brain microvessels. Biochim Biophys Acta 1978;526:537-46.

454. Arinami T, Li L, Mitsushio H, Itokawa M, Hamaguchi H, Toru M. An insertion/deletion polymorphism in the angiotensin converting enzyme gene is associated with both brain substance P contents and affective disorders. Biol Psychiatry 1996;40:1122-7.

455. Macdonald RL, Pluta RM, Zhang JH. Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution. Nat Clin Pract Neurol 2007;3:256-63.

456. Hossmann KA. Pathophysiology and therapy of experimental stroke. Cell Mol Neurobiol 2006;26:1057-83.

457. Werner C, Engelhard K. Pathophysiology of traumatic brain injury. Br J Anaesth 2007;99:4-9.

458. Sugawara T, Jadhav V, Ayer R, Chen W, Suzuki H, Zhang JH. Thrombin inhibition by argatroban ameliorates early brain injury and improves neurological outcomes after experimental subarachnoid hemorrhage in rats. Stroke 2009;40:1530-2.

459. Yu Z, Cheng G, Huang X, Li K, Cao X. Neurokinin-1 receptor antagonist SR140333: a novel type of drug to treat cerebral ischemia. Neuroreport 1997;8:2117-9.

460. Wahl F, Grosjean-Piot O, Bareyre F, Uzan A, Stutzmann JM. Enoxaparin reduces brain edema, cerebral lesions, and improves motor and cognitive impairments induced by a traumatic brain injury in rats. J Neurotrauma 2000;17:1055-65.

461. Donkin JJ, Nimmo AJ, Cernak I, Blumbergs PC, Vink R. Substance P is associated with the development of brain edema and functional deficits after traumatic brain injury. J Cereb Blood Flow Metab 2009;29:1388-98.

462. Kook YA, Lee SK, Son DH, et al. Effects of substance P on osteoblastic differentiation and heme oxygenase-1 in human periodontal ligament cells. Cell Biol Int 2009;33:424-8.

463. Cyrino LA, Cardoso RC, Hackl LP, Nicolau M. Effect of quercetin on plasma extravasation in rat CNS and dura mater by ACE and NEP inhibition. Phytother Res 2002;16:545-9.

464. Traystman RJ. Animal models of focal and global cerebral ischemia. Ilar J 2003;44:85-95.

465. Small DL, Buchan AM. Animal models. Br Med Bull 2000;56:307-17.

466. Leker RR, Constantini S. Experimental models in focal cerebral ischemia: are we there yet? Acta Neurochir Suppl 2002;83:55-9.

467. Carmichael ST. Rodent models of focal stroke: size, mechanism, and purpose. NeuroRx 2005;2:396-409.

References

182

468. Andaluz N, Zuccarello M, Wagner KR. Experimental animal models of intracerebral hemorrhage. Neurosurg Clin N Am 2002;13:385-93.

469. Asahi M, Asahi K, Wang X, Lo EH. Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats. J Cereb Blood Flow Metab 2000;20:452-7.

470. Winkler DT, Bondolfi L, Herzig MC, et al. Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J Neurosci 2001;21:1619-27.

471. Bullock R, Mendelow AD, Teasdale GM, Graham DI. Intracranial haemorrhage induced at arterial pressure in the rat. Part 1: Description of technique, ICP changes and neuropathological findings. Neurol Res 1984;6:184-8.

472. MacLellan CL, Silasi G, Poon CC, et al. Intracerebral hemorrhage models in rat: comparing collagenase to blood infusion. J Cereb Blood Flow Metab 2008;28:516-25.

473. Deinsberger W, Vogel J, Kuschinsky W, Auer LM, Boker DK. Experimental intracerebral hemorrhage: description of a double injection model in rats. Neurol Res 1996;18:475-7.

474. Waugh DF, Anthony LJ, Ng H. The interactions of thrombin with borosilicate glass surfaces. J Biomed Mater Res 1975;9:511-36.

475. Belayev L, Saul I, Curbelo K, et al. Experimental intracerebral hemorrhage in the mouse: histological, behavioral, and hemodynamic characterization of a double-injection model. Stroke 2003;34:2221-7.

476. Choudhri TF, Hoh BL, Solomon RA, Connolly ES, Jr., Pinsky DJ. Use of a spectrophotometric hemoglobin assay to objectively quantify intracerebral hemorrhage in mice. Stroke 1997;28:2296-302.

477. Rosenberg GA, Estrada E, Kelley RO, Kornfeld M. Bacterial collagenase disrupts extracellular matrix and opens blood-brain barrier in rat. Neurosci Lett 1993;160:117-9.

478. MacLellan CL, Auriat AM, McGie SC, et al. Gauging recovery after hemorrhagic stroke in rats: implications for cytoprotection studies. J Cereb Blood Flow Metab 2006;26:1031-42.

479. Floor E, Leeman SE. Substance P sulfoxide: separation from substance P by high-pressure liquid chromatography, biological and immunological activities, and chemical reduction. Anal Biochem 1980;101:498-503.

480. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 4th ed. San Diego: Academic press; 1998.

481. Turner R. Characterising the role of substance P in acute ischaemic stroke. . Adelaide: University of Adelaide; 2007.

482. Seabrook GR, Shepheard SL, Williamson DJ, et al. L-733,060, a novel tachykinin NK1 receptor antagonist; effects in [Ca2+]i mobilisation, cardiovascular and dural extravasation assays. Eur J Pharmacol 1996;317:129-35.

483. O'Connor CA, Cernak I, Vink R. Interaction between anesthesia, gender, and functional outcome task following diffuse traumatic brain injury in rats. J Neurotrauma 2003;20:533-41.

484. Jeong SW, Chu K, Jung KH, Kim SU, Kim M, Roh JK. Human neural stem cell transplantation promotes functional recovery in rats with experimental intracerebral hemorrhage. Stroke 2003;34:2258-63.

485. Schallert T, Woodlee MT. Orientation and Placing. In: Whishaw I, Kolb B, eds. The behaviour of the laboratory rat: a handbook with tests. Oxford: Oxford University Press; 2005:129-40.

486. Schallert T, Woodlee MT, Fleming SM. Disentangling multiple types of recovery from brain injury. In: Kriegelstein J, Klump S, eds. Pharmacology of cerebral ischaemia. Stuttgary: Medpharm Scientific Publishers; 2002:201-16.

487. Barth TM, Jones TA, Schallert T. Functional subdivisions of the rat somatic sensorimotor cortex. Behav Brain Res 1990;39:73-95.

References

183

488. Olsson M, Nikkhah G, Bentlage C, Bjorklund A. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 1995;15:3863-75.

489. Borlongan CV, Randall TS, Cahill DW, Sanberg PR. Asymmetrical motor behavior in rats with unilateral striatal excitotoxic lesions as revealed by the elevated body swing test. Brain Res 1995;676:231-4.

490. Nan Z, Grande A, Sanberg CD, Sanberg PR, Low WC. Infusion of human umbilical cord blood ameliorates neurologic deficits in rats with hemorrhagic brain injury. Ann N Y Acad Sci 2005;1049:84-96.

491. De Ryck M. Animal models of cerebral stroke: pharmacological protection of function. Eur Neurol 1990;30 Suppl 2:21-7; discussion 39-41.

492. Elliott KA, Jasper H. Measurement of experimentally induced brain swelling and shrinkage. Am J Physiol 1949;157:122-9.

493. Reis ML, Okino L, Rocha e Silva M. Comparative pharmacological actions of bradykinin and related kinins of larger molecular weights. Biochem Pharmacol 1971;20:2935-46.

494. Yamaza T, Kido MA, Wang B, et al. Distribution of substance P and neurokinin-1 receptors in the peri-implant epithelium around titanium dental implants in rats. Cell Tissue Res 2009;335:407-15.

495. Li Q, Goodchild AK, Pilowsky PM. Effect of haemorrhage on the expression of neurotransmitter-related genes in rat ventrolateral medulla: a quantitative real-time RT-PCR study. Brain Res Mol Brain Res 2003;114:46-54.

496. van Wijngaarden P, Brereton HM, Coster DJ, Williams KA. Stability of housekeeping gene expression in the rat retina during exposure to cyclic hyperoxia. Mol Vis 2007;13:1508-15.

497. Pohjanvirta R, Niittynen M, Linden J, Boutros PC, Moffat ID, Okey AB. Evaluation of various housekeeping genes for their applicability for normalization of mRNA expression in dioxin-treated rats. Chem Biol Interact 2006;160:134-49.

498. Cook N, Van Den Heuvel C, Donkin J, Vink R. Validation of reference genes for normalization of real-time quantitative RT-PCR data in traumatic brain injury. Journal of Neuroscience Research 2009;87:34-41.

499. Wilhelm J, Pingoud A. Real-time polymerase chain reaction. ChemBioChem 2003;4:1120-8.

500. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biology 2007;8.

501. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biology 2002;3:research0034.1-.11.

502. Ruifrok AC, Johnston DA. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol 2001;23:291-9.

503. Colour deconvolution ImageJ macro. (Accessed May 7th, 2008, at http://www.dentistry.bham.ac.uk/landinig/software/software.html.)

504. van der Loos CM. Multiple immunoenzyme staining: methods and visualizations for the observation with spectral imaging. J Histochem Cytochem 2008;56:313-28.

505. Turner R, Vink R. Inhibition of neurogenic inflammation as a novel treatment for ischemic stroke. Timely Top Med Cardiovasc Dis 2007;11:E24.

506. Kleinig TJ, Helps SC, Ghabriel MN, et al. Hemoglobin crystals: a pro-inflammatory potential confounder of rat experimental intracerebral hemorrhage. Brain Res 2009;1287:164-72.

507. Marmarou A. A review of progress in understanding the pathophysiology and treatment of brain edema. Neurosurg Focus 2007;22:E1.

References

184

508. Farina C, Aloisi F, Meinl E. Astrocytes are active players in cerebral innate immunity. Trends Immunol 2007;28:138-45.

509. Dong Y, Benveniste EN. Immune function of astrocytes. Glia 2001;36:180-90.

510. Nimmo AJ, Cernak I, Heath DL, Hu X, Bennett CJ, Vink R. Neurogenic inflammation is associated with development of edema and functional deficits following traumatic brain injury in rats. Neuropeptides 2004;38:40-7.

511. Hartel K, Schnell C, Hulsmann S. Astrocytic calcium signals induced by neuromodulators via functional metabotropic receptors in the ventral respiratory group of neonatal mice. Glia 2009;57:815-27.

512. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Ann Neurol 2006;59:467-77.

513. Macleod MR, Fisher M, O'Collins V, et al. Good laboratory practice: preventing introduction of bias at the bench. Stroke 2009;40:e50-2.

514. Diener HC, Lees KR, Lyden P, et al. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke 2008;39:1751-8.

515. Macleod MR, van der Worp HB, Sena ES, Howells DW, Dirnagl U, Donnan GA. Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality. Stroke 2008;39:2824-9.

516. Crossley NA, Sena E, Goehler J, et al. Empirical evidence of bias in the design of experimental stroke studies: a metaepidemiologic approach. Stroke 2008;39:929-34.

517. Fisher M, Feuerstein G, Howells DW, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009;40:2244-50.

518. Park SW, Yan YP, Satriotomo I, Vemuganti R, Dempsey RJ. Substance P is a promoter of adult neural progenitor cell proliferation under normal and ischemic conditions. J Neurosurg 2007;107:593-9.

519. Tang T, Li XQ, Wu H, Luo JK, Zhang HX, Luo TL. Activation of endogenous neural stem cells in experimental intracerebral hemorrhagic rat brains. Chin Med J (Engl) 2004;117:1342-7.

520. Privat A, Leblond CP. The subependymal layer and neighboring region in the brain of the young rat. J Comp Neurol 1972;146:277-302.

521. Masuda T, Isobe Y, Aihara N, et al. Increase in neurogenesis and neuroblast migration after a small intracerebral hemorrhage in rats. Neurosci Lett 2007;425:114-9.

522. Morshead CM, van der Kooy D. Postmitotic death is the fate of constitutively proliferating cells in the subependymal layer of the adult mouse brain. J Neurosci 1992;12:249-56.

523. Xue M, Yong VW. Matrix metalloproteinases in intracerebral hemorrhage. Neurol Res 2008;30:775-82.

524. Wasserman JK, Schlichter LC. Neuron death and inflammation in a rat model of intracerebral hemorrhage: effects of delayed minocycline treatment. Brain Res 2007;1136:208-18.

525. Wasserman JK, Schlichter LC. Minocycline protects the blood-brain barrier and reduces edema following intracerebral hemorrhage in the rat. Exp Neurol 2007;207:227-37.

526. Wolberg AS, Campbell RA. Thrombin generation, fibrin clot formation and hemostasis. Transfus Apher Sci 2008;38:15-23.

527. Lee KR, Betz AL, Keep RF, Chenevert TL, Kim S, Hoff JT. Intracerebral infusion of thrombin as a cause of brain edema. J Neurosurg 1995;83:1045-50.

528. Yang GY, Betz AL, Hoff JT. The effects of blood or plasma clot on brain edema in the rat with intracerebral hemorrhage. Acta Neurochir Suppl (Wien) 1994;60:555-7.

529. Nagatsuna T, Nomura S, Suehiro E, Fujisawa H, Koizumi H, Suzuki M. Systemic administration of argatroban reduces secondary brain damage in a rat model of intracerebral hemorrhage: histopathological assessment. Cerebrovasc Dis 2005;19:192-200.

References

185

530. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005;3:1800-14.

531. Hua Y, Keep RF, Gu Y, Xi G. Thrombin and brain recovery after intracerebral hemorrhage. Stroke 2009;40:S88-9.

532. Murphy RC, Seegers WH. Concentration of Prothrombin and Ac-globulin in various species. Am J Physiol 1948;154:134-9.

533. Xi G, Keep RF, Hua Y, Xiang J, Hoff JT. Attenuation of thrombin-induced brain edema by cerebral thrombin preconditioning. Stroke 1999;30:1247-55.

534. Lee KR, Drury I, Vitarbo E, Hoff JT. Seizures induced by intracerebral injection of thrombin: a model of intracerebral hemorrhage. J Neurosurg 1997;87:73-8.

535. Donkin J. The effects of the neuropeptide substance P on outcome following traumatic brain injury in rats. Adelaide: University of Adelaide; 2006.

536. Yang S, Song S, Hua Y, Nakamura T, Keep RF, Xi G. Effects of thrombin on neurogenesis after intracerebral hemorrhage. Stroke 2008;39:2079-84.

537. Jiang Y, Wu J, Hua Y, et al. Thrombin-receptor activation and thrombin-induced brain tolerance. J Cereb Blood Flow Metab 2002;22:404-10.

538. Lin Q, Li D, Xu X, Zou X, Fang L. Roles of TRPV1 and neuropeptidergic receptors in dorsal root reflex-mediated neurogenic inflammation induced by intradermal injection of capsaicin. Mol Pain 2007;3:30.

539. McCluskey LP, Lampson LA. Local immune regulation in the central nervous system by substance P vs. glutamate. J Neuroimmunol 2001;116:136-46.

540. Hughes SR, Williams TJ, Brain SD. Evidence that endogenous nitric oxide modulates oedema formation induced by substance P. Eur J Pharmacol 1990;191:481-4.

541. Brownstein MJ, Mroz EA, Kizer JS, Palkovits M, Leeman SE. Regional distribution of substance P in the brain of the rat. Brain Res 1976;116:299-305.

542. Ruocco HH, Fernandes GA, Namer IJ, Depaulis A, Levy S. Hypothalamic response to experimental allergic encephalomyelitis: role of substance P. Neuroimmunomodulation 2004;11:28-35.

543. Tsushima H, Mori M. Central injections of capsaicin cause antidiuresis mediated through neurokinin-1 receptors in rat hypothalamus and vasopressin release. Jpn J Pharmacol 1999;79:237-41.

544. Wang Y, Novotny M, Quaiserova-Mocko V, Swain GM, Wang DH. TRPV1-mediated protection against endotoxin-induced hypotension and mortality in rats. Am J Physiol Regul Integr Comp Physiol 2008;294:R1517-23.

545. Michael-Titus AT, Fernandes K, Setty H, Whelpton R. In vivo metabolism and clearance of substance P and co-expressed tachykinins in rat striatum. Neuroscience 2002;110:277-86.

546. James TA, Starr MS. Effects of substance P injected into the substantia nigra. Br J Pharmacol 1979;65:423-9.

547. Matute C, Domercq M, Sanchez-Gomez MV. Glutamate-mediated glial injury: mechanisms and clinical importance. Glia 2006;53:212-24.

548. Fan TP, Hu DE, Guard S, Gresham GA, Watling KJ. Stimulation of angiogenesis by substance P and interleukin-1 in the rat and its inhibition by NK1 or interleukin-1 receptor antagonists. Br J Pharmacol 1993;110:43-9.

549. Seegers HC, Hood VC, Kidd BL, Cruwys SC, Walsh DA. Enhancement of angiogenesis by endogenous substance P release and neurokinin-1 receptors during neurogenic inflammation. J Pharmacol Exp Ther 2003;306:8-12.

References

186

550. Ajmo CT, Jr., Vernon DO, Collier L, et al. The spleen contributes to stroke-induced neurodegeneration. J Neurosci Res 2008;86:2227-34.

551. William BM, Thawani N, Sae-Tia S, Corazza GR. Hyposplenism: a comprehensive review. Part II: clinical manifestations, diagnosis, and management. Hematology 2007;12:89-98.

552. Buttenschoen K, Buttenschoen DC, Berger D, et al. Endotoxemia and acute-phase proteins in major abdominal surgery. Am J Surg 2001;181:36-43.

553. Kariko K, Weissman D, Welsh FA. Inhibition of toll-like receptor and cytokine signaling--a unifying theme in ischemic tolerance. J Cereb Blood Flow Metab 2004;24:1288-304.

554. Rosenzweig HL, Minami M, Lessov NS, et al. Endotoxin preconditioning protects against the cytotoxic effects of TNFalpha after stroke: a novel role for TNFalpha in LPS-ischemic tolerance. J Cereb Blood Flow Metab 2007;27:1663-74.

555. Klassert TE, Pinto F, Hernandez M, et al. Differential expression of neurokinin B and hemokinin-1 in human immune cells. J Neuroimmunol 2008;196:27-34.

556. Quartara L, Maggi CA. The tachykinin NK1 receptor. Part II: Distribution and pathophysiological roles. Neuropeptides 1998;32:1-49.

557. Walsh DT, Weg VB, Williams TJ, Nourshargh S. Substance P-induced inflammatory responses in guinea-pig skin: the effect of specific NK1 receptor antagonists and the role of endogenous mediators. Br J Pharmacol 1995;114:1343-50.

558. Rasley A, Marriott I, Halberstadt CR, Bost KL, Anguita J. Substance P augments Borrelia burgdorferi-induced prostaglandin E2 production by murine microglia. J Immunol 2004;172:5707-13.

559. Xi G, Reiser G, Keep RF. The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective? J Neurochem 2003;84:3-9.

560. Hamada R, Matsuoka H. Antithrombin therapy for intracerebral hemorrhage. Stroke 2000;31:794-5.

561. Hill MD. Stroke: the dashed hopes of neuroprotection. Lancet Neurol 2007;6:2-3.

562. Hua Y, Nakamura T, Keep RF, et al. Long-term effects of experimental intracerebral hemorrhage: the role of iron. J Neurosurg 2006;104:305-12.